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Background/aim of the study: Cancer-associated fibroblasts (CAFs) are a heterogenous 
population of cells found in the stroma of tumor. It is well known that CAFs are involved in 
many aspects of the development, progression and metastasis of cancer. The main objective in 
this thesis is to study how CAFs from non-small cell lung carcinoma (NSCLC) are able to 
regulate the immune functions of monocyte-derived dendritic cells (DCs) and to investigate if 
ionizing radiation have measurable effects on CAF-mediated modulation on DCs.  
Methods: Primary cultures of CAFs were isolated from newly resected NSCLC tumor 
specimens (n=4) gathered at the Tromsø University Hospital, whereas buffy coats from 
unrelated healthy donors were used for isolation of peripheral blood mononuclear cells 
(PBMCs). CD14+ monocytes were isolated from PBMCs and stimulated to generate immature 
monocyte-derived dendritic cells (iDCs) and mature monocyte-derived dendritic cells (mDCs). 
The experimental settings comprised both DC/CAFs co-cultures and incubation of DCs with 
CAF-conditioned medium (CAF-CM). Effects from either non-irradiated or irradiated (3x6 Gy 
or 1x18 Gy) CAFs were compared. DCs phenotype and function were determined by; 
expression of cell surface activation markers (CD14, CD1a, CD209, CD40, CD80, CD86 and 
HLA-DR), functional assays (antigen uptake, DCs migration T cell priming) and cytokine 
production (IL-10 and IL-12).  
Results: We demonstrated that CAFs in both CAF-CM and co-culture experiments have the 
capability to suppress functional markers for DCs. In addition, CAFs inhibited DCs ability to 
internalize antigens, migratory capacity, priming of T cells and down-regulated production of 
IL-10 and IL-12 by DCs. Further, irradiation of CAFs, especially with fractioned regiments 
curtailed the inhibitory effects exerted by CAFs over DCs.   
Conclusion: This study demonstrated that CAF-derived soluble molecules could mediate 
immunosuppressive effects upon DCs. Further, results illustrate that irradiation of CAFs with 
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1 Introduction  
1.1 Tumor immunology: General Principles  
Immunology is a branch within biology that studies the immune system of different organisms. 
The immune system works to eradicate foreign pathogenic microorganisms and other materials 
that are regarded as a threat to the body and is generally divided in two different branches; the 
innate and the adaptive immune system [1]. The innate immune system can be regarded as 
the first line of defense and is comprised of both soluble recognition molecules as well as 
cellular components. Cells in the innate immune system includes phagocytic cells (e.g. 
macrophages), antigen presenting cells (e.g. dendritic cells) and killer cells (e.g. natural 
killer cells). These cells preform a non-specific elimination of a foreign microbial invasion or 
tissue damage and are very effective [2]. In comparison, the adaptive immune system has a 
specific reaction to a unique danger signal. The adaptive immune system consists of antigen 
specific T- and B cells and also a broad diversity of antibodies and cytokines produced by the 
cellular components of the system [3]. 
An immune response is orchestrated in two phases; the activation/effector phase and the 
resolution/immunosuppressive phase. Tumor immunology investigate the correlation between 
the resolution/immunosuppressive phase and cancer, since tumors try to disrupt signals in this 
phase to avoid immune responses [4]. Cancer cells form when non-reversible changes occur in 
the DNA of cells, which allows these cancer cells to lose normal cellular regulatory processes 
[5]. The immune system will detect these cancer cells as a threat and launch an attack to 
eliminate the uncontrolled cells in a process known as immunosurveillance [6]. The conception 
that there is a link between the immune system and cancer was proposed by Rudolph Virchow 
over 150 years ago and this concept has now been acknowledged for over a century [7]. But it 
was Paul Ehrlich who first hypothesized that cancers can be eliminated by the immune system 
[8]. Burnet and Thomas later supported the hypothesis of Ehrlich which lead to the theory of 
immunosurveillance [6]. 
1.1.1 Cancer immunoediting: The 3 “Es” model  
Recent years of research have led to an extended concept of the immunosurveillance theory. 
This new conception is called cancer immunoediting and tries to explain the different phases 
that can occur in relation to immune system – cancer interactions. The process of 
immunoediting is a dynamic process and is composed of three different phases; elimination, 




Figure 1.1: The three “Es” of cancer immunoediting: Normal cells are able to break free from control 
mechanisms due to changes in DNA and generates cells with corrupt DNA. The first “E” describes the 
phase of elimination were immune cells are able to recognize and eliminate cancer cells before the 
tumor becomes clinically detectable. If some variant of the cancer cells is not eliminated, these cells 
may introduce the second phase of immunoediting and the next “E”, which stands for equilibrium. In 
this phase, T cells and other factors keep the tumor in a dormant state and might be able to stop the 
tumor from growing further. The final “E” stands for escape and represents the last phase of 
immunoediting. Tumor cells can adapt genomic changes that allow them to escape recognition by the 
immune system and continue growing to a possible clinically detectable tumor [10]. 
 
The first phase of cancer immunoediting is elimination and refers to immunosurveillance. In 
this phase, both the innate and the adaptive immune system works together in recognition and 
elimination of normal cells transformed to cancer cells that have gained the ability to escape 
tumor suppression through blocking of intrinsic cell mechanisms. In this elimination process, 
which can be thought of as a selection process, some subclones of tumors can circumvent  the 
elimination process due to the genetically instable nature of tumor cells that could lead to 
downregulation of antigen presenting molecules and/or an increase in programmed death-




Equilibrium is the second phase of cancer immunoediting were some tumor cells have escaped 
the elimination phase. In this stage of the cancer immunoediting concept a dynamic balance 
take place between cells of the immune system and tumor cells. Some studies have found that 
high numbers of CD8+ T cells, natural killer (NK) cells, T cells and low numbers of NKT 
cells, Foxp3+ Treg cells and myeloid-derived suppressor cells (MDSCs) can be correlated with 
control of tumor growth and keep the tumor in the equilibrium phase [12]. 
The third “E” and final phase is escape. There are several factors that can lead to immune 
escape for tumors, including loss of recognition by the immune system, reduced expression of 
major histocompatibility complex (MHC) class I molecules and/or co-stimulatory molecules. 
Regardless why, the result is that the immune system fails in restriction of tumor growth and 
tumor cells will be capable to grow into a clinical detectable tumor [9].  
 
 Biology of tumor microenvironment  
Tumors are complex tissues formed by malignant cells and a combination of non-malignant 
components that together gives support to the tumor and is frequently referred to as tumor 
microenvironment (TME) or tumor stroma. The TME consist of many different cellular and 
acellular components such as extracellular matrix (ECM), illustrated in Figure 1.2. Other cells 
besides the tumor cells includes mesenchymal cells, immune cells and vascular cells. These 
cells together with non-cellular factors of the ECM contribute to the heterogeneity of tumors in 
numerous ways. One main difference between tumor cells and other cells found in the TME is 
that tumor cells have been formed by several mutations in DNA that has led to the formation 
of cells able to grow uncontrolled. Non-malignant cells found in the TME are cells with intact 





Figure 1.2: Overview of the tumor microenvironment: TME consists of a broad diversity of cells and 
ECM that contributes to the heterogeneity of tumor stroma. Cells found in tumor stroma includes 
fibroblasts, vascular endothelial cells and immune cells [14]. 
 
 Mechanisms of cancer immune evasion  
If the immune system should fail, cancer cells evade detection and eradication by the immune 
cells and can grow uncontrolled. Several different mechanisms, or a combination of them, can 
be used by cancer cells for being able to break free from the control of the immune system. 
1.3.1 Antigenicity  
The immune system distinguish normal cells from malignant cells by antigens presented on the 
surface of cells [15]. These “foreign” antigens or neo-antigens produced by cancer cell emanate 
from genetic mutations in tumor cells, which is a hallmark of cancer, and is one of the primary 
factors for generating specific neo-antigens [16]. The process were the immune system 
recognize and kills cancer cells can be referred to as the Cancer-Immunity Cycle, which is a 
stepwise process. In general, immune cells recognize the tumor antigens and generates an 
immune response to eliminate cells with the specific “foreign” antigens displayed on their 
surface [17]. Still, the tumor cells can acquire the ability to hide their identity as malignant cells. 
One of the most common strategies for cancer cells to avoid being identified by immune cells 
is to downregulate the expression of MHC class I molecules on their surface and by doing so 




But the immune system has a method for detecting and destructing cells that downregulate their 
expression of MHC class I molecules. One of the cell types found in the innate immune system, 
NK cells, have the ability to identify and kill cells that downregulate the expression of MHC 
class I molecules [20]. Cells with unnaturally reduced expression of MHC class I molecules 
fail to provide NK cells with enough inhibitory signals to retain the NK cells in an inactivated 
state thus activating the NK cells. This enables the NK cells to kill target cells by lysis [21]. 
However, tumors can use other suppressive signals to evade immune attack. The Natural Killer 
Group 2D (NKG2D) receptor is expressed by NK cells and is one of the key receptors in 
recognizing stress-induced ligands” such as MICA, MICB and ULBP1-6. The interaction 
NKG2D/NKG2D ligand is one of the important mediators of recognizing and killing tumors. 
But tumor cells can manipulate the expression of NKG2D ligands on a post-transcriptional or 
post-translational level which reduces the expression of stress-signals and thus escaping 
immune recognition by NK cells [22]. 
1.3.2 Co-stimulatory and co-inhibitory receptors interactions 
Cancer evasion strategies include the regulation of different co-stimulatory and co-inhibitory 
receptors displayed on the surface of immune cells. The full activation of T cells requires two 
signals. The primary signal is mediated through T cell receptor (TCR) – MHC molecule 
interactions. The secondary signal is provided through co-stimulatory/co-inhibitory molecules 
presented on the surface T cells (Figure 1.3). These co-stimulatory/co-inhibitory molecules can 
interact with surface receptors on antigen presenting cells (APCs) [23]. The process from 
antigen recognition to killing of cancer cells are in the Cancer-Immunity Cycle divided in two 
phases; the priming phase and the effector phase [24]. Co-stimulatory molecules are necessary 
in the priming phase to activate T cells by antigen presenting cells (APC), such as B7-1 
(CD80)/B7-2 (CD86) – CD28 interactions, which is one of the strongest signals in activating T 
cells. But the expression of co-stimulatory molecules for immune cells can be downregulated 
in tumor stroma [25], and lacking the co-stimulatory signals through B7-1/B7-2 could lead to 
a hyperresponsive state/anergy for T cells [23].    
The co-stimulatory molecules CD80/CD86 also have affinity for cytotoxic T-lymphocyte 
associated protein 4 (CTLA4) on T cells. The interaction provide T cells with an inhibitory 
signal, limiting the priming of T cells and an immune response [26]. Another important 
interaction regarding immune response is between PD-1L and PD-1. Various cells express PD-




with PD-1 found on T cells and the interaction can lead to suppression of T cells responses [30]. 
The balance between these stimulatory and inhibitory signals are important for the effect of the 
immune response. Newer studies have demonstrated that immune checkpoint can be expressed 
by tumor cells, which can provide cancer cells with properties for evading the cytotoxic 
capability of T cells [31].  
 
Figure 1.3: Co-stimulatory and co-inhibitory signaling: A broad diversity of molecules are expressed 
on the surface of APCs and T cells. Some interactions provide co-stimulatory signals, which leads to 
the priming of T cells, such as B7-1/B7-2 and CD28. An inhibitory signal, on the other hand, is produced 
when B7-1/B7-2 interacts with CTLA4, which could result in reduced priming of T cells. Another 
important interaction is between PD-1 – PD-1L, which leads to suppression of T cell response [32]. 
 
1.3.3 Avoiding cell death 
Immune cells and other factors, such as stress, can induce cell death (apoptosis) in cancer cells. 
The process of apoptosis is a cellular suicide program that gives an organism the possibility to 
eliminate unwanted cells [33]. Tumor cells have the ability to resist cell death and become 




Cancer cells are, in contrast to normal cells, suffering from different forms of stress, such as 
genomic instability, cellular hypoxia and oncogenic stress [35]. Cancer cells also experience 
other factors such as DNA damage and growth factor deprivation [36]. All these factors would 
in normal cells lead to cell death trough the intrinsic pathway of apoptosis, but cancer cells gain 
mechanisms to avoid this by suppressing pro-apoptotic protein expression. Important initiator 
molecules for the intrinsic pathway of apoptosis are BH3-only molecules, which belongs to a 
family of proteins called Bcl-2 family [37]. The BH3-only molecules are pro-apoptotic, but 
there are also other members of the same family of proteins that are anti-apoptotic, and the 
balance between these pro-apoptotic and anti-apoptotic molecules decides if a cell enters 
intracellular death program or not [38]. Most of human cancers acquire mutations in the p53 
tumor suppressor gene, which shut down the expression of p53 proteins. The p53 protein 
regulates the process of apoptosis through interactions with Bcl-2 proteins, and when the p53 
is inactivated, this leads to an elevated concentration of anti-apoptotic Bcl-2 family proteins, 
which tips the balance in favor for anti-apoptotic molecules which support cancer cell survival 
[39, 40]. 
1.3.4 Cellular metabolism 
Cells are dependent on energy to fulfill their functions. One of the most important energy 
sources for cells is glucose, but cells can also use lipids or amino acids to generate energy in 
the form of adenosine triphosphate (ATP). The primary pathway of generating energy for cells 
in the presence of oxygen is through mitochondrial oxidative phosphorylation (OXPHOS), 
which generates more energy by oxidization of glycose in comparison to aerobic glycolysis 
[41]. In 1956, the German scientist Dr. Otto Warburg stated that cancer cells rewire their 
metabolism and start to generate energy through aerobic glycosylation even in the present of 
oxygen. This process is later known as the Warburg effect [42]. Aerobic glycosylation seems 
to be an inefficient way to generate energy for cells, since more ATP is generated from 
OXPHOS compared to aerobic glycosylation. But, the rate of glucose metabolism is 10-100 
times faster in aerobic glycosylation than the total oxidation of glucose in mitochondria, which 
explain why aerobic glycosylation provides cancer cells with their high demand in energy more 
suitable than oxidation in mitochondria [43]. 
But the change in metabolism for cancer cells towards Warburg biology does not only support 
cancer cells with energy. It also contributes to immune suppression as well. Immune cells, like 




of cancer cells. Upon activation, the metabolic demand for these immune cells increases and 
there is a competition between cancer cells and immune cells for required metabolites in the 
TME. When cancer cells starts to increase their consumption of glucose, less becomes available 
for immune cells and can result in limited functions for the immune cells crucial for elimination 
of tumor cells [44]. 
1.3.5 Immunosuppressive cells    
Tumors can escape the immune system by triggering the recruitment of immunosuppressive 
cells. Recruitment is mediated by tumor-induced cytokine production, such as transforming 
growth factor- (TGF-) and CXCL5 [45]. Mechanisms used by immunosuppressive cells to 
dampen immune attack include; reduce antigen presentation by DCs, increased production of 
arginase, inducible nitric oxide synthase (iNOS) and indoleamine-2,3-dioxygenase (IDO) to 
prevent the proliferation and activation of B- and T cells, secretion of immunosuppressive 
cytokines IL-10 and TGF- and inhibition of the cytotoxic function of T lymphocytes and NK 
cells [9]. In Figure 1.4, an illustrated overview can be seen of immune cells recruited to the 
TME and signal molecules involved in the recruitment. 
 
Figure 1.4: Immunosuppressive cells: Cancer cells secrete a broad diversity of cytokines and 
chemokines which promotes the recruitment of immunosuppressive cells such as MDSCs, regulatory T 
cell (Treg), tumor-associated macrophages (TAMs), T helper 17 cell (Th17), regulatory dendritic cell 
(DCreg), tumor-associated neutrophil (TAN) and regulatory B cells (Breg). These cells contributes to 
produce a immunosuppressive environment in TME that can switch the phenotype and function of 




One of the immune cells recruited into the TME are tumor-infiltrating (TI) Tregs. The 
recruitment is mediated through mechanism involving CCL22 produced by tumor cells and 
TAMs [46], which is a ligand for CCR4 found on Treg [47]. Accumulation of Tregs in tumor 
stroma can lead to modulating of function for other immune cells recruited to the tumor by 
various mechanism. Normally, Tregs function to maintain immune homeostasis. This is 
accomplished by different suppressive cellular and humoral mechanisms, which involves 
surface receptors CTLA-4 and CD25, and the production of inhibitory cytokines such as IL-10, 
TGF- and IL-35. Treg cells can also degrade ATP and express granzyme and/or perforin, which 
enables Tregs to kill other cells [48]. The functions for Tregs is illustrated in Figure 1.5. Th17 
T helper cells represents a CD4+ T cell lineage different from Th1, Th2 and Tregs. This 
inflammatory cell type is found in significant numbers inside tumors, where Th17 T cells 
secrete the pro-inflammatory cytokine IL-17 contributing to tumorigenesis [49].  
 
Figure 1.5: Functions of Treg cells: The suppressive functions of Tregs are mediated through the  CTLA-
4 pathway, expression of immunosuppressive cytokines IL-10 and TGF- and killing target cells 
through secretion of granzyme and/or perforin [48].  
 
MDSCs are also one of the major cell types recruited to TME and that facilitate tumor immune 
evasion. This type of cell represents a heterogenous population of cells which participates in 
numerous different immunological functions because they are able to differentiate into 
granulocytes, macrophages or DCs [50]. MDSCs are recruited to TME by a broad range of 
different chronic inflammatory factors, such as IL-1, IL-4, IL-5, IL-10, TGF- and many other 




Once the MDSCs are in the TME, a vast spectrum of different suppressive molecules are 
secreted to tumor stroma. Arginase is expressed by MDSCs and is a crucial molecule in urea 
cycle for converting L-arginine to L-ornithine and urea, which reduces available L-arginine for 
T cells. T cell uses L-arginine in  metabolic pathways for survival and anti-tumoral activity 
[52], and the lack of L-arginine leads to translational blockage for infiltrating T cells causing 
inhibition of T cell proliferation  [53, 54]. In addition, this results in downregulation of TCR -
chain, which is essential for T cell signaling and causes T cell anergy [55]. iNOS is expressed 
by MDSCs to catabolize L-arginine, which could lead to T cell anergy as well [56]. MDSCs 
can also express PD-L1 used to suppress T cells responses directly. Other molecules expressed 
by MDSCs are reactive oxygen species (ROS) and TGF-, which can suppress NK cells 
synthesis IFN- [57]. There are two types of macrophages; type I (M1) and type II (M2). The 
M1-polarized macrophages have an inflammatory function while M2-polerized macrophages 
also known as TAMs, have anti-inflammatory activity [58]. TAMs are heterogenic cells due to 
their monocytic precursor, but also based on their various functions. These alternative activated 
M2-polerized macrophages are activated by IL-10 and TGF- and exert their function by 
secretion of an anti-inflammatory and wound-healing cytokine profile, which includes IL-4, IL-
10 and IL-13 [59]. Another important immunosuppressive cell in the TME are stromal 
fibroblasts or CAFs. The biology of this cell type including their immunoregulatory functions 
will be described in more detail later in the introduction.  
 
 Cancer-associated fibroblasts (CAFs) 
CAFs represent a major component of the tumor stroma and are involved in many aspects in 
the progression of tumors [60]. To understand the role of fibroblasts in cancer development, 
knowledge has been transferred from the concept of wound healing. Tumors are frequently seen 
and understood as “wounds that do not heal”. This was first identified by Rudolf Virchow in 
1863 in the way that “chronic irritation and inflammatory hyperplasia are predispositions for 
cancer development”. This way of thinking in relation to cancer was further denoted almost 90 
years later in 1974 by Alexander Haddow who proposed that “tumor production is a possible 
overhealing”. But the notion that tumors are wounds that did not heal was not proper recognized 
before Harold F. Dvorak in 1986 published an assay in the New England Journal of Medicine 




Fibroblasts are an abundant cell type found in connective tissue throughout the body. These 
cells become activated when tissues are damaged, and undergo differentiation into 
myofibroblasts [62]. Normally, the physiological role of myofibroblasts is synthesis and 
secretion of ECM components, mostly collagens, to influence the composition of ECM, 
maintaining tissue homeostasis and inflammation, and differentiation of surrounding cells. 
Because of these features, CAFs can be seen as architects of TME [63, 64]. Myofibroblasts are 
destined for apoptosis when repair of damaged tissue is finalized [65]. When cancer cells start 
to grow, this is interpreted as a wound for the body, which activates fibroblasts. But in this 
situation, the activated fibroblasts fail to undergo apoptosis and are able to support and become 
an critical factor of the tumor stroma [66]. Cancer cells recruit and activate CAFs by secretion 
of many different signal molecules within the TME, and one of the main factors are TGF-. 
But other pro-fibrotic factors such as platelet-derived growth factor (PDGF), basic fibroblast 
growth factor (bFGF) and IL-6 are important as well [67]. 
1.4.1 The heterogenic nature of CAFs  
The majority of CAFs originate from resident fibroblasts [68]. But CAFs can also derive from 
other precursor cells such as epithelial cells [69], endothelial cells [70], resident stem cells [71], 
transdifferentiated smooth muscle cells [72], trans-differentiated adipocytes [73], bone-marrow 
derived mesenchymal cells [74] and local mesenchymal cells [75] (Figure 1.6). CAFs are able 
to maintain their phenotype for several passages when cultured in vivo compared to normal 
fibroblasts. This suggest that CAFs have been through genetic or epigenetic changes which 
results in the special characteristics of CAFs [76, 77]. 
Figure 1.6: Origin of cancer-associated fibroblasts: CAFs can originate from various populations of 
cells by different mechanism. This includes endothelial cells, resident stem cells, transdifferentiated 
smooth muscle cells, transdifferentiated adipocytes, bone marrow-derived mesenchymal cells, local 




There is variation between CAFs due to the heterogenic nature and high plasticity of CAFs, 
which makes it hard to determine specific markers for CAFs. But there has been established 
certain positive markers to identify and isolate CAFs from other cells [79]. The most used 
positive marker for identification of CAFs are -smooth muscle actin (-SMA) even though 
not all functionally activated CAFs express this marker [80]. Other markers used for CAFs are 
fibroblast activation protein (FAP) [81], tenascin-c (TNC) [82], podoplanin (PDPN) [83] and 
neuron-glial Antigen-2 (NG2) [84]. CAFs also increased the secretion of ECM proteins such 
as fibronectin and type I collagen, which can also be used as functional markers [85]. Cell-
associated molecules, such as platelet-derived growth factor receptors a/b (PDGFR a/b), 
vimentin (VIM), fibroblast-specific protein-1 (FSP-1) and periostin (POSTN) are markers for 
fibroblast as well, but not specific markers for CAFs. Table 1.1 represents a list of positive 
surface markers for both normal fibroblast and CAF [79]. 
 
















Mainly expressed by non-myofibroblast subpopulations of CAFs 
Consider to be the most positive marker for CAFs  
The expression of MFAP5 varies amongst the populations of CAFs  
Suggested to be very specific for identification of CAFs  
A myofibroblast-associated marker. Important factor for metastasis 
Can be overexpressed by some subclasses of CAFs. Also expressed by tumor cells 
and macrophages  
Upregulated by CAFs related to non-small cell lung cancer 
Marker of some CAF subclasses. Numerous other cells also express this marker such 




















Very common marker for identification of fibroblasts  
A widely expressed marker by all fibroblasts  
Common used marker for quiescent fibroblasts  
Expressed by both normal fibroblasts and CAFs 











Newer studies have suggested that different subclasses of CAFs might co-exist within tumor 
stroma. An illustration of the hypothesis can be seen in Figure 1.7. It is proposed that one 
subclass of CAFs are restraining tumor development (F1), while another subclass can support 
tumor (F2). There is also hypothesized that some specialized CAFs has a secretory phenotype, 
which can support tumor immunity, cancer cell survival, apoptosis and angiogenesis (F3) and 
some CAFs with a particular phenotype enabling them to remodel ECM through secretion of 
ECM components (F4) [86]. This has been confirmed by newer studies. In 2018, Bartoschek et 
al were able to identify three different subpopulations of breast-cancer related CAFs by 
techniques using a negative selection strategy in combination with single cell RNA sequencing 
for detection of different types of CAFs based on their transcription of genes and thereby their 
phenotype [87].  
 
Figure 1.7: CAF subclasses: It is hypothesized the existents of different subtypes of CAFs within the 
TME with distinct functions regarding tumor development based on CAFs phenotype. CAFs with the F1 
phenotype are thought to have a tumor restraining type, while the F2 type of CAFs have properties 
enabling this phenotype to promote tumor development. CAFs with F3 phenotype have secretory 
capabilities and are involved in many aspects of tumor progression. The concept also supports the idea 
of another type, the F4 CAFs, which are mainly involved in the remodeling of ECM by secretion of 




1.4.2 CAFs role in tumor progression 
It was originally thought that cancer cells are self-sufficient for tumor progression, but recent 
studies have revealed stromal cells such as CAFs with essential roles in tumor development 
[60]. A crucial feature of tumors are the initiation of tumor vasculature in a process known as 
angiogenesis. This provides the rapidly growing tumor with nutrients and oxygen, and also 
contributes to remove waste products [88]. One of the most pro-angiogenic molecule is vascular 
endothelial growth factor (VEGF) which regulates growth of new vessels through mechanisms 
related to Hypoxia inducible factor-1 (HIF-1) [89]. CAFs can support tumor angiogenesis 
through secretion of VEGF, but also by secretion of PDGF and TGF- [90, 91]. Stromal derived 
factor-1 (SDF-1), also known as CXCL12, is also synthesized and secreted by CAFs, which 
promotes the recruitment of endothelial precursor into tumor stroma, supporting the formation 
of tumor angiogenesis [92, 93]. IL-6 is a pleiotropic cytokine with a number of pro-tumorigenic 
activities including angiogenesis through endothelial proliferation and migration [94], and 
CAFs are an important source for stromal IL-6 [95, 96].  
Another key aspect of CAFs in support of tumor progression is through ECM remodeling [97]. 
ECM is a non-cellular but physiologically active component of the tumor stroma, and is 
important for cell-cell communication, cell adhesion and cell proliferation [98]. Fibroblasts 
normally produce stromal ECM components such as fibronectin and I, III and V collagens in 
addition to matrix metalloproteinases (MMPs) for assembly and degradation of ECM [99]. 
CAFs, due to their activated nature, are engaged in an abnormal production of ECM 
components and produce increased levels of fibronectin, collagen I and MMPs. Such changes 
in ECM components can support cancer cell migration and invasion [100]. Metastasis is a 
hallmark of cancer and is the process were cancer cells are able to detach from the primary 
tumor site, enter the circulation and develop secondary tumors [101]. CAFs support cancer cell 
metastasis by initiation of angiogenesis and altering the ECM by mechanisms mentioned above 









Figure 1.8: CAFs role in tumor progression: CAFs are an important contributor in the TME by 
secretion of different factors. Angiogenesis is promoted by CAFs by mechanism involving secretion of 
VEGF and IL-6, which is aided by CAFs remodeling of ECM through secretion of ECM components 
such as collagens, fibronectin and MMPs [86]. 
An important step for cancer cells to metastasize is to migrate from primary tumor location. 
This is done through a mechanism named epithelial-mesenchymal transition (EMT).  The 
process of EMT is a developmental process were epithelial cells transdifferentiate into 
mesenchymal cells which enables the cells to migrate to new regions. EMT is silent in normal 
cells, but is reactivated in cancer [103]. One of the key changes for cancer cell EMT is the 
downregulation of inter-cellular adhesion molecules E-cadherin. CAFs can support cancer cells  
EMT by secretion of hepatocyte growth factor (HGF) and TGF-, which promote paracrine 
signaling in cancer cells and induces EMT [104, 105]. Some studies have suggested that CAFs 
have the ability to detach from tumor stroma, enter the circulation and continue tumor support 
at metastatic sites [91]. 
1.4.3 CAFs role in anti-tumor immune responses 
There is not only a cross-communication between cancer cells and immune cells, but between 
CAFs and immune cells as well. Although very frequently ignored by immunologists due to 
their non-hematopoietic origin, CAFs are one of the most important immunoregulatory cells in 




include CXCL1, CXCL2, CXCL5, CXCL6/GCP-2, CXCL8, CXCL9, CXCL10, 
CXCL12/SDF-1 CCL7, IL-1β, IL-6, IL-10, VEGF, TGF-β, IDO, prostaglandin E2 (PGE2), 
tumor necrosis factor (TNF), soluble NKG2D ligands or nitric oxide (NO) [107]. The 
communication between CAFs and different types of immune cells can be seen in Figure 1.9. 
Macrophages is one of the immune cell types found in TME. CAFs secretion of CXCL12/SDF-
1, macrophage colony-stimulating factor (M-CSF) and IL-6 stimulate recruitment of monocytes 
to TME and the differentiation of monocytes into M2-polerized macrophages to support tumor 
progression [108].  
γδ T cells are one of three immune cell subclasses that express antigen receptor and this cell 
type has different approaches to promote its anti-tumor surveillance. One of the main action of 
γδ T cells is their cytotoxic activity, which is provided by production of chemokines and 
components of cytotoxic granules including perforin, granzyme, tumor necrosis factor and 
TNF-related apoptosis-inducing ligand [109]. γδ T cells can also act as a bridge between the 
innate and the adaptive immune system by activation of B cells and aid the humoral immunity 
[110]. Cells of the TME, including CAFs, are able to regulate the proliferation and function of 
γδ T cells through secretion of TGF-, PGE2, adenosine and soluble NKG2D ligands 
(MICA/B). These signal molecules can polarize γδ T cells from IFN- producing cells to IL-17 
producing γδ T cells [111]. CAFs can also suppress the activity of NK cells. The different 
immunological functions for NK cells includes “cross-talk” with DCs, which provides 
activating stimuli for both NK cells and DC [112]. NK cells have cytotoxic properties and are 
able to recognize and kill cancer cells through NKG2D receptor, which binds MHC class I 
molecules on target cells/cancer cells [22]. CAFs are able to decrease NK cell activation and 
cytotoxic function by secretion of TGF-, PGE2 and/or IDO. These molecules affects NK cells 
by reducing the transcription of DAP12, resulting in a downregulation of NK activation 
receptors such as NKp30, NKp40 and NKG2D and the expression of perforin and granzyme. It 
also alters the expression of IFN- for NK cells, which is a stimulating factor for effector CD4 









Figure 1.9: Signaling between CAFs and immune cells: CAFs secrete a broad spectrum of signal 
molecules, which enables CAFs to “talk” with immune cells within the TME. This communication can 
alter the function of the immune cells towards pro-tumorigenic phenotypes [107]. 
 Dendritic cells  
Dendritic cells (DCs) belongs to the innate immune system and are one of the key cellular 
components regarding immune responses. They can be regarded as a bridge between the innate 
and adaptive immune system [113]. It was known in the 1960s that lymphocytes exerted the 
function of the adaptive immune system, but it was not known how lymphocytes become active. 
Between 1967 and 1973, an exceptional cell type was discovered with the capability to take up 
antigens, and it was identified that this type of cell, called A cells or the third cell, was 
responsible for activation of T lymphocytes and antibody related responses. In 1973, Ralph 
Steinman and Zanvil Cohn unveiled a cell type with phagocytic characteristic and a morphology 
with dendritic structures. And because of these structures, the cell type was named dendritic 
cells. It turned out that the same cell discovered between 1967-1973 and the cell type identified 
by Steinman and Cohn was the same type of cell, the dendritic cell [114].  
The majority of cells in the immune system can be found in different functional stages in order 
to best confront different challenges. This is also the case with DCs, comprising different 




to engage the adaptive immune system. All the different subsets of DCs originate from 
hematopoietic stem cells. The four major subsets of DCs are; (1) conventional type 1 dendritic 
cell (cDC1), (2) conventional type 2 dendritic cell (cDC2), (3) plasmacytoid dendritic cells 
(pDCs), and (4) monocyte-derived dendritic cells (Mo-DCs) [115] (Figure 1.10). From this 
point on, the focus will be on Mo-DCs since this subset of DCs are used in the study. 
 
Figure 1.10: Different dendritic cell populations: DCs belongs to the hematopoietic cell linage, which 
starts with hematopoietic stem cells (HSC). These cells give rise to the common myeloid progenitors 
(CMPs), and the transcription factor Nur77 regulates differentiation into monocytes, which can be 
further development into monocyte-derived dendritic cells (Mo-DCs) during inflammatory conditions. 
If Nur77 is not activated, CMPs are differentiated by several steps into common dendritic cell progenitor 
(CDP) which can be further differentiated to conventional type 1 DC (cDC1), conventional type 2 DC 
(cDC2) and plasmacytoid DC (pDC). Critical transcription factors for development of the different 
subclasses are showed. Different markers for each subclass can be seen in green [115]. 
 
1.5.1 General biology of DCs  
DCs are specialized leucocytes considered as APCs. They are generally found in peripheral 
tissues and immunological organs, such as the spleen, thymus, bone marrow, lymph nodes and 
Peyer`s patches [116]. They are part of the primary line of defense for humans with the ability 
to detect invading bacterial, viral, protozoan and fungal pathogens or other foreign molecules 
[117]. Macrophages (Mø) are found in all organs and tissues and are also part of our first line 
of defense. Mø secret IL-4 and granulocyte-macrophage colony-stimulating factor (GM-CSF) 
upon detection of danger signals, which in turn trigger the transformation of monocytes to 




and NK cells through MHC class I molecules deriving from intracellular proteins to initiate 
immune responses, but DCs have a special ability to take up peptides from the environment, 
internalize, and present the antigens through MHC class II molecules to CD4 T cells in lymph 
nodes and launch a full scale adaptive immune response [119].  
1.5.1.1 Antigen uptake 
iDCs are able to internalize extracellular foreign antigens through different mechanism. This 
includes receptor-mediated endocytosis, phagocytosis and micropinocytosis [120]. The 
pathway generating MHC class I and MHC class II molecules with antigens can be seen in 
Figure 1.11. Endogenous proteins are processed by proteasomal proteolysis by proteasomes, 
which generates peptides able to translocate from cytosol to endoplasmic reticulum (ER). Here, 
peptides bind to MHC class I molecules, and these peptide-MHC class I complexes are further 
transported through the Golgi apparatus to the cell membrane for antigen presentation [121]. 
This pathway is also important for a cross-presentation, which is an important pathway APCs 
can use to present exogenous peptides through MHC class I molecules to CD8 T cells [122]. 
iDCs use a broad variety of pattern recognition receptors (PPRs) such as toll-like receptors 
(TLRs), C-type lectins (CLRs) and nucleotide oligomerization domain-like receptors (NLRs) 
to detect and capture infectious exogenous non-self-antigens [123]. These exogenous peptides 
are internalized by endocytosis and processed through a vesicular pathway ending with 
displaying peptide fragments (antigens) through MHC class II molecules on the surface of 
mDCs [124]. As with foreign peptides, cancer cells produces pathogen-associated molecular 
patters (DAMPs) released from dead cancer cells which are recognized as danger signals by 
iDCs. Death of cancer cells can be caused by hypoxia or nutrient deprivation, which generates 
host-derived DAMPs, resulting in display of cancer peptides on the surface of DCs [125]. Upon 
recognition of danger signals by PPRs, iDCs start the maturation process leading to the 
generation of mDCs. The maturation process can also be initiated by inflammatory cytokines, 






Figure 1.11: Antigen uptake: Endogenous proteins in cytosol are processed by proteasome generating 
peptide fragments, which are then translocated to ER. Here, peptide fragments are assembled with MHC 
class I which are then displayed on the surface of cell with antigen. Exogenous proteins are internalized 
by iDCs and then processed through late endosomes were peptides are combined with MHC class II 
molecules and further transported to the cell membrane for display to cells in the adaptive immune 
system [121].  
 
1.5.1.2 Migration 
While iDCs are specialized in recognition of DAMPs and processing foreign antigens, mDCs 
are specialized in presentation of internalized peptides to T cells. During the maturation process, 
DCs modulate the expression pattern of chemokine receptors, and downregulation phagocytosis 
and endocytosis. The maturation process also involves an upregulated expression of MHC class 
II molecules, adhesion molecules (CD54) and co-stimulatory molecules CD80 and CD86 for 
optimizing the properties necessary for T cell priming capacity [128, 129]. One of the key 
signals for initiation of DC maturation is mediated through TLRs, which results in downstream 
signaling and activation of nuclear factor-B (NF-B), which regulates gene expression of co-
stimulatory molecules, MHC molecules and chemokine receptor 7 (CCR7) [130]. Other surface 
markers are also increased upon maturation of DCs, such as MHC class II (HLA-DR) and CD40 




expression of both IL-10 and IL-12, while mDCs have negative to low expression of IL-10 and 
medium to high expression of IL-12 [128]. The migration mediated by CCR7 is important for 
migration of mDCs towards lymph nodes and an illustration of the migration can be seen in 
Figure 1.12. This migration is driven by the chemokines CCL19 and CCL21, which act as 
ligands for CCR7. These two chemokines are synthesized by lymphatic endothelial cells and T 
cells in the lymph nodes, helping to guide the mDCs towards its target cells [132]. 
 
Figure 1.12: Migration of mDCs: Upon recognition and internalization of foreign antigens, iDCs start 
to migrate towards lymph nodes driven by an upregulation of chemokine receptors. During the 
migration, DCs change phenotype towards a mature state, which is specialized in presentation of 
antigens and activation of naïve T cells in lymph nodes for initiation of an adaptive immune response 
[133].  
 
1.5.1.3 Antigen presentation  
The lymph nodes are comprised of different compartments with their own niche for immune 
cells. Antigen presenting mDCs migrate towards the paracortex of lymph nodes were they 
encounter naïve CD4+ T cells [134]. Here, mDCs are able to present antigens to naïve CD4+ T 
cells, which leads to the differentiation of naïve CD4+ T cells to different subclasses of T cells 




eliminate target cells who are displaying antigens similar to the ones presented by mDCs [135, 
136]. One mDC is able to interact with as many as approximately 5000 T cells per hour, to 
illustrate the enormous capacity of mDCs to display antigen to T cells [137]. The full activation 
of naïve CD4+ T requires two signals; (1) interaction between MHC class II (with antigen) and 
TCR, and (2) interaction between co-stimulatory molecules CD80/CD86 and CD28, as can be 
seen illustrated in Figure 1.13 [117]. mDCs display CD40 on its surface as well, which can be 
used to interact with CD40L and activate CD4+ T cells. These activated CD4 T cells can further 
communicate with B-cells and aid the humoral immunity [138].  
 
Figure 1.13: Antigen presentation: mDCs present antigens to naïve CD4+ T cells through MHC class 
II – TCR integration. This signaling represents signal 1, but the fully activation of naïve CD4+ T cells 
requires another signal, signal 2, which is provided by interactions between the co-stimulator molecules 
CD80/CD86 and CD28 [139]. 
 
1.5.2 Dendritic cells in cancer  
DCs are the foundation of the “cancer immunity cycle” as illustrated by Chen and Mellman 
(2013) in Figure 1.14. This illustration gives an overview of the function of DCs together with 
T cells and the cycle involves several steps which eventually lead to the death of cancer cells; 
(1) cancer cells release antigens due to cancer cell death, (2) which is recognized by DCs and 
presented to T cells in lymph nodes. (3) This leads to priming and activation of T cells, (4) 
resulting in migration of T cells to tumor site. (5) Here, tumor-specific T cells infiltrate tumors, 
(6) and recognize cancer cells by surface antigens (7) leading to the death of cancer cells 





Figure 1.14: Cancer immunity cycle: DCs and T cells cooperate to kill cancer cells in what is known 
as the “cancer immunity cycle” [17]. 
 
But, tumors can interfere at all stages in the “cycle” trying to escape the immune system. DCs 
are mainly involved in the three first steps, and cancer cells can induce either apoptosis of DCs 
or polarization towards a tolerogenic and immunosuppressive phenotype for immune evasion 
[140]. Apoptosis can be induced in DCs through mechanisms involving production of tumor-
derived gangliosides and HMGB1 [141]. Decoy receptor 3 (DcR3) or tumor necrosis factor 
receptor (TNFR) have ability to induce apoptosis for DCs as well. The level of DcR3 is elevated 
in a number of different cancers and is used as a biomarker to predict inflammatory disease 
progression and cancer metastasis [142]. DcR3 is able to induce apoptosis in DCs through 
pathways including protein kinase C  (PKC-) and c-Jun N-terminal kinase (JNK), leading to 
up-regulation of death receptor 5 (DR5) causing recruitment of Fas-associated death domain 
(FADD) to promote apoptotic signals for DCs [143]. 
Tumor stroma can also educate DCs to become immunosuppressive, and these DCs are known 
as regulatory DCs (DCreg). The generation of DCreg from normal DCs is mediated through 
the broad variety of immunosuppressive factors tumors produce, such as NO, IL-10, IL-6, 




types of cancer, such as breast, colorectal, lung, renal, head and neck, bladder, gastric and 
ovarian [144]. The formation of DCreg prevents T cells from being activated by DCs through 
antigen presentation followed by interruption of priming and activation of T cell [145]. This 
affects all T cell mediated immune responses towards tumors.   
Tumor cells not only block the activation of T cell-mediated immune response by DCs, but also 
suppress T cell activity in tumor stroma by the generation of DCreg. Normally, DCreg are 
important for maintaining the equilibrium needed between inflammatory responses and 
tolerance. There is a clear distinction between the immature phenotype of DCs with the ability 
to take up antigens and the mature phenotype for presentation of such antigens. But in regard 
to DCreg, this is less clear. It was initially demonstrated that iDCs are able to induce tolerance, 
which could be explained by the fact that iDCs process antigens, and in the absence of co-
stimulatory molecules induce T cell anergy and deletion. But newer research has revealed that 
mDCs can induce immunosuppressive functions as well, which suggest that DCreg is a 
functional state rather than a special subclass that can be defined by certain phenotypic markers 
[131]. 
Tumor-induced DCreg can be characterized by the combination of surface marker expression 
and cytokine production. This involves markers such as PD-L1, PD-L2, B7-H3, B7-H4, 
CD103, ILT3/4. Cytokines synthesized and other immunoregulatory factors produced by 
DCreg include IL-10, IL-1, TGF-, IDO, arginase I and iNOS. In addition, DCreg express 
low levels of CD11c, MHC class II and co-stimulatory molecules CD80 and CD86. By these 
mechanisms, DCreg are able to affect and alter the function of T cells in all aspects of the 
“tumor immunity cycle” [146]. By the lack of MHC class II molecules, DCreg are not fitted to 
provide T cells with the necessary signal 1 for activation or signal 2 provided by co-stimulatory 
molecules CD80/CD86 for full T cell activation. Other surface receptors, such as the inhibitory 
ligands B7-H3, B7-H4, can bind to unknown receptors on T cells and reduce the proliferation 
of T cells [147]. Figure 1.15 gives an overview of receptors found on APCs and T cells 




Figure 1.15: Co-stimulatory and inhibitory receptors mediate T cell responses: Antigen-presenting 
cells express both co-stimulatory and inhibitory receptors on their surface to mediate different T cell 
responses [148]. 
 
 Radiation and the tumor microenvironment  
There are many different types of cancer treatments. This includes cytostatic chemotherapy, 
radiotherapy (RT), immunotherapy, hormone therapy, targeted therapy and surgery or a 
combination of these treatments [149-153]. Over 50 % of all diagnosed cancer patients go 
through RT during the course of disease, which makes RT one of the most used treatment 
modalities in oncology [154]. Treatment regarding RT was first used to target and kill cancer 
cells themselves because of the thought that only cancer cells contributed to the development 
of disease. In recent years, the understanding that tumors are not solely dependent on cancer 
cells, but also surrounding stromal cells, has led to new strategies involving RT where TME is 
the target for RT as well [155]. RT is able to trigger anti-tumor effects beyond the direct killing 
of malignant cells. On a molecular level, RT is able to induce non-reparable damage to cell 
DNA and this results in cellular stress and apoptosis. The use of RT can also affect leukocytes, 




blood [156]. Not only does RT affect the intended area, but other localizations as well. This 
phenomenon is known as the abscopal effect and can be thought of as an systemic anti-tumor 
immune response [157].  
1.6.1 Effect of radiotherapy on antitumor immunity 
When RT is applied locally, affected cells die and releases immunogenic factors through a 
process known as immunogenic cell death (ICD) [158]. ICD is characterized by the increase of 
endogenous DAMPs, which includes calreticulin (CRT), HMGB-1 and ATP [159]. DCs are 
activated by elevated levels of DAMPs, which in turn activates T lymphocytes through antigen 
presentation. Both HMGB-1 and ATP are able to act directly on DCs through binding of Toll-
like receptor 4 (TLR-4) and purine receptor, respectively [160]. Binding of HMGB-1 stimulates 
production of cytokines TNF, IL-1, IL-6 and IL-8 by monocytes and also enhances DCs antigen 
presentation by preventing degradation of antigens within DCs, while binding of ATP leads to 
synthesis of IL-1. The release of chemokines CXCL10 and CXCL16 as a response to RT can 
induce migration of T cells to tumor stroma. It has also been reported that low-dose RT can 
mobilize NO expressing macrophages to tumors with the ability to stabilize tumor vasculature 
[161] (Figure 1.16). 
Figure 1.16: Effect of radiotherapy: Immunogenic cell death is induced by RT, which results in release 
of DAMPs, such as HMGB-1, ATP and calreticulin. DAMPs generates an immune response by binding 
to DCs, leading to activation of cytotoxic T lymphocytes (CTL). RT also triggers production of  




1.6.2 Effect of RT on TME 
The effects of RT on tumor vasculature depends on some factors. How tumor blood vessels 
react to RT depends on number of fractions, dose rate, total radiation dose and fraction size 
[162]. Additionally, quiescent endothelial cells are more resistant to RT compare to 
proliferating endothelial cells and there is evidence supporting rapid death of vasculature 
initiated by singe high-dose irradiation, and also reduced vascular density with hyper 
fractionated irradiation [163]. The induced apoptosis for vascular endothelial cells as a result 
from RT contributes to the starvation of cancer cells and the elevation of hypoxia. The 
elimination of vasculature for tumors can result in a hypoxic and acidic tumor 
microenvironment with limited nutrition. This can cause indirect death of cancer cells [162]. 
CAFs, being one of the most abundant cell types in tumor stroma, are also affected by RT. 
Normal fibroblasts and CAFs are relatively radioresistant cells and are able to withstand RT 
doses above 50 Gy. But there are in vitro studies demonstrating that RT doses >10 Gy induces 
an irreversible state of senescence for fibroblasts, and low-dose RT results in reversible DNA 
damage without growth arrest. Fibroblasts in a senescence state synthetize proteolytic enzymes, 
cytokines, growth factors and reactive oxygen species (ROS) able to cause a pro-tumorigenic 
environment [164]. Another study demonstrated that immunosuppressive molecules secreted 
by CAFs, such as PGE2, IL-6, IL-10 and TGF- remain unchanged after RT of CAFs [165]. 
Knowledge about the effect irradiation has on CAFs immunosuppression is still poor. In this 
study, we wanted to investigate the effect of RT on CAF-mediated immunomodulation 












2 Aim of study 
Cancer-associated fibroblasts are one of the most abundant components found in the tumor 
microenvironment. Studies have demonstrated  that radiotherapy could lead to permanent 
phenotypic changes for the CAFs.  Immune cells recruited to the TME can be “educated” by 
CAFs to gain immunosuppressive phenotypes creating a pro-tumorigenic TME, but the 
mechanisms behind this alteration is still poorly understood  
The purpose of this study was to investigate the influence of RT on CAFs modulation of DCs 
phenotype and functions in an in vitro setting. The main objective was divided in the following 
sub-aims: 
- Characterize potential effects of CAFs on DCs phenotype differentiation/maturation 
- Characterize potential effects of CAFs on DCs immune functions 





















3 Material  
 
 Cell culture medium and supplements 
 Catalog number Supplier Origin 
Classical Medium - - - 
Dulbecco`s Modified Eagle 
Medium (DMEM) 
D5796 Sigma-Aldrich USA 
Roswell Park Memorial 
Institute (RPMI) 
R8758 Sigma-Aldrich USA 
Bronchial Epithelial Basal 
Medium (BEBM) 
CC-3171 Lonza Belgium 
Supplements - - - 
Fetal Bovine Serum (FBS) S0115 Biochrom Germany 
Insulin-Transferrin-
Selenium 
25-800-CR Corning USA 
Sodium Pyruvate (100 mM) 11360070 Gibco UK 
Penicillin-Streptomycin P4333 Sigma-Aldrich USA 
L-ascorbic Acid A92902 Sigma-Aldrich USA 
Accutase Cell Detachment 
Solution 
561527 BD Biosciences USA 
Complete DMEM growth medium 
DMEM with 10 % FBS + Penicillin-Streptomycin + L-ascorbic acid 
Complete RPMI growth medium 
RPMI + 10 % FBS + Penicillin-Streptomycin + Pyruvate 
CAFs Freezing medium 
RPMI + 60 % FBS + 10 % DMSO 
PBMC/Lymphocytes/dendritic cells Freezing medium  







 Cell Culture Reagents  
 Catalog number Supplier Origin 
Cell Detachment - - - 
Enzyme Free Cell 
Dissociation Solution PBS 
Based  
S-014-B Millipore Norway 
Trypsin-EDTA solution T4049 Sigma Aldrich USA 
Cell Freezing - - - 
Dimethyl Sulfoxide 
(DMSO) 
20385.01 Serva Germany 
PBMC Isolation - - - 
LymphoprepTM 1114544 Axis-Shield Norway 
Cell Washing - - - 
Phosphate Buffer Saline 
(PBS) 
D8537 Sigma Aldrich Germany 
 
 Supplies 
 Catalog number Supplier Origin 
Plastic ware - - - 
NuncEasyFlask 
25cm2 
163371 ThermoScientific Denmark 
NuncEasyFlask 
75cm2 
156499 ThermoScientific Denmark 
NuncEasyFlask 
175cm2 
159910 ThermoScientific Denmark 
Falcon Tissue 
Culture Dish Sterile 
353003 Corning USA 
Falcon 6-well plates 
TC-treated  
353046 Corning  USA 
Falcon 24-well 
plates TC-treated 





 Antibodies and recombinant proteins 
 Catalog number Supplier Origin 
Human IL-4 200-04-50UG PeproTech USA 
Human GM-CSF 300-03-50UG PeproTech USA 
Human IL-1 200-01B-50UG PeproTech USA 
Human TNF- 300-01A-50UG PeproTech USA 
Human IL-6 200-06-50UG PeproTech USA 
Prostaglandin E2 P5640 Sigma-Aldrich Norway 
Human CCL19 (MIP-3) 130-105-744 Miltenyi Biotec USA 
Human anti-CD1a  130-111-875 Miltenyi Biotec USA 
Human anti-CD14 130-110-522 Miltenyi Biotec USA 
Human anti-CD209  130-099-727 Miltenyi Biotec USA 
Human anti-CD80 130-101-213 Miltenyi Biotec USA 
Human anti-CD86 130-116-159 Miltenyi Biotec USA 
Human anti-CD40  130-110-946 Miltenyi Biotec USA 
Human anti-HLA-DR 130-111-797 Miltenyi Biotec USA 
 
 MACS cell separation products 
 Catalog number Supplier Origin 
MACS Multistand 130-042-303 Miltenyi Biotec USA 
MidiMACS separator 130-042-302 Miltenyi Biotec USA 
CD14 Microbeads 130-091-097 Miltenyi Biotec USA 
CD4 T Cell Isolation Kit 130-094-131 Miltenyi Biotec USA 
LS Columns 130-042-401 Miltenyi Biotec USA 
MACS BSA Stock Solution 130-091-379 Miltenyi Biotec USA 
autoMACSTM Rinsing 
Solution 






 FACS flow product 
 Catalog number Supplier Origin 
Reagents    
FACS Flow 342003 BD Biosciences Canada 
FACS Rinse 340346 BD Biosciences Canada 
Tubes    
Falcon Polystyrene Round-
Bottom tube 5 ml 
352054 Corning USA 
 
 Other supplies 
 Catalog number Supplier Origin 
25cm Cell Scraper 734-2602 VWR UK 
Stainless sterile blade 90010-23 Paragon USA 
Falcon tube 15 ml 734-0451 VWR UK 
Falcon tube 50 ml 734-0448 VWR UK 
BD PlastiPak Syringe 302188 ThermoScientific USA 
Syringe Filter Unit Z355518-50EA Millex Norway 
Pasteur pipette 7ml sterile LSUK726128 VWR UK 
Nunc CryoTube Vails  363401 ThermoScientific Denmark 




FITC dextran  60842-46-8 Sigma-Aldrich Norway 
CellTraceTM C34557 ThermoScientific Denmark 
 
 Instruments Supplier Origin 
Heraeus Miltifuge X3 Centrifuge ThermoScientific Germany 
Eppendorf 5417R centrifuge Eppendorf Germany 
Grant Sub Aqua Pro Water Bath VWR UK 






Heracell 150 ThermoScientific Germany 
Heracell 150i ThermoScientific Germany 
Nikon Eclipse TS100 Nikon Thailand 
Incubating Mini Shaker VWR UK 
 
 Kits 
 Catalog number Supplier Origin 
Human IL-12 DuoSet®  DY1240-05 R&D Systems USA 
Human IL-10 DuoSet® DY217B-05 R&D Systems USA 
 
 Elisa reagents 
 Catalog number Supplier Origin 
Reagent Diluent concentration 1 DY997 R&D Systems USA 
Color Reagent A and B DY999 R&D Systems USA 
Tween 20  P416 Sigma-Aldrich USA 
Sulphuric Acid (H2SO4)  100731 Millipore Germany 
HEPES H3784  Sigma-Aldrich USA 
Sodium Hydroxide (NaOH) 71690 Sigma-Aldrich USA 
Wash Buffer  WA126 R&D Systems USA 
Reagent concentration 2  DY995 Sigma-Aldrich USA 
Normal Goat Serum DY005 R&D Systems USA 
Tris 72H5601 Sigma-Aldrich USA 
Sodium Chloride K26478104917 MERCK  Germany 
 
 Software  Supplier Origin 
CellQuestTM Pro Software BD Bioscience  USA 
Flow Jo Office V10 Tree Star USA 
BD FACSdivaTM  Software BD Bioscience USA 
Ascent Software  Thermo Electron Corporation USA 




SoftMax Pro Software Molecular Devices USA 
Excel 2018 Microsoft USA 
GrapPad Prism 7  GraphPad USA 































4 Methodology  
The following sections describes the methods used in the study. Flowchart presented in Figure 
4.1 gives an overview of methods and direction in the course of the study.  
 
Figure 4.1: Flowchart of the study: CAFs were isolated from tumor specimens resected from patients 
with NSCLC and expanded in monolayers. Buffy coats were used for isolation of PBMCs, which was 
further used to isolate naïve CD4+ T cells and CD14+ monocytes. Monocytes were differentiated into 
iDCs and mDCs followed by incubation with non-irradiated or irradiated CAF-CM/co-culture with 
CAFs. The immunomodulatory effects of CAFs on DCs was explored by analysis of surface marker 
assays, cytokine expression with IL-10 and IL-12 and functional assays (antigen uptake, migration and 





 Ethical statement 
All blood samples from healthy individuals and tumor specimens from patients with NSCLC 
were anonymously obtained and written consent was given from all individuals in accordance 
with the Declaration of Helsinki. This study is approved by the Regional Ethical Committee 
(REK# 2016/2307, 2016/714, 2014/40). Methods involving the use of human material was done 
following the proper regulations and guidelines.  
 
 Biological samples and Patients 
Human tumor samples were obtained from four different patients with NSCLC at Tromsø 
University Hospital of Northern Norway, and information regarding donors is described in 
Table 4.1. Patients used in the study had not received any additional therapy before tumor 
biopsy samples were collected. Concentrated leucocyte blood samples (buffy coat) were 
received from unrelated healthy donors from the University Hospital of Northern Norway blood 
bank.  
Table 4.1: Overview of tumor sample donors 
Number Age Sex Tumor Type T-size (mm) T-stage N-stage 
Donor 1 71 M Squamous cell carcinoma  35  2a 0 
Donor 2 68 M Squamous cell carcinoma 22 1c 0 
Donor 3 71 F Adenocarcinoma  25 1 0 
Donor 4 65 M Squamous cell carcinoma 30 3 0 
Abbreviations: M=Male, F=Female 
N-stage=0: Tumor has not spread to nearby lymph nodes 
 
 
 Isolation and culture of cancer-associated fibroblasts from NSCLC 
4.3.1 Selection of cell source: Primary cells  
Our laboratory chose to work with human primary cells cultures (cells directly isolated from 
human tissue and cultured in vitro) over cells lines (immortalized cells) because the primary 
cells display closer phenotypic characteristics similar to the original tissue. This enables more 




tumor tissue fibroblasts have a restricted proliferation capacity and can ultimately reach the 
state of replicative senescence (permanent growth arrest). Fibroblasts from already established 
cells lines have transformed phenotypes with frequently chromosomal aberrations resulting in 
abnormal cells with unlimited proliferation capacity [167]. When working with human primary 
cell cultures, a limitation one may experience is change of original features of the primary 
culture each time cells are passaged (subcultures). Because of these changes, it is important to 
use cells that have been expanded for short periods and the same number of times to ensure that 
the result from experiments are similar.  
4.3.2 Isolation and cell culture procedures   
Human biopsy samples were collected from the pathology department of Tromsø University 
Hospital within few after surgical resection from patients with NSCLC. Tubes with tumor 
biopsies were sterile and contained Dulbecco`s Modified Eagle`s Medium (DMEM). Samples 
were processed quickly to make sure biopsy specimen were in best condition as possible for 
further studies.  
The four following steps were done to ensure the correct isolation and culturing of primary 
NSCLC CAFs: 
- Tissue digestion  
- Enzyme-free detachment of cells 
- Cell passage of CAFs 
- Cryopreservation of primary tumor CAFs 
 
Tissue digestion 
Tissue was received in a 50 mL falcon tube. Solution from falcon tube was extracted, leaving 
just enough solution to cover the biopsy sample. Solution with tissue were then poured into a 
sterile petri dish and cut in smaller pieces (1-1.5 mm3) with surgical blades. Tumor biopsy 
pieces were put together within 5 mL of 400 IU - Accutase (Dulbecco’s PBS (0.2 g/L KCl, 0.2 
g/L KH2PO4, 8 g/L NaCl, and 1.15 g/L Na2HPO4) containing 0.5 mM EDTA (4Na and 3 mg/L 
Phenol Red) and transferred to a T-25 cell culture flask and subjected to enzymatic digestion 
for 60 minutes by placing the T-25 flask on an incubating mini shaker at 37ºC. Afterwards, 
tumor tissue samples were eagerly shaken to redeem cells in the pieces. Tumor fragments were 




collagenase. Supernatants were discarded, and pellets resuspended in 12 mL of fresh complete 
CAF growth medium containing DMEM supplemented with 10 % fetal bovine serum (FBS) 
and 1 % penicillin streptomycin. Then, 2 mL of cell suspension was added in each well in 6-
well tissue culture plate. Tumor pieces were divided equal amongst the wells and the plate was 
placed in a cell culture incubator at 37ºC with low oxygen (3% O2), which allowed cells to 
become attached to the solid substrate.  
CAFs isolation  
Each well contained a mixture tumor-derived cells the day after tissue digestion, primarily 
tumor cells and fibroblasts. For fibroblast enrichment, medium from all 6 wells was first 
removed and 2 mL of pre-warmed Phosphate Buffered Saline (PBS) were then filled and kept 
in each well for 1-2 minutes. Afterwards, PBS were removed and replaced with Enzyme-Free 
solution, which promotes selective detachment of fibroblasts while maintaining the structural 
integrity of cell surface proteins. Plates were placed in culture incubator at 37ºC low oxygen 
(3% O2) for 10 minutes. Wells were afterwards examined with microscope to validate CAFs 
detachment from wells. If observations with microscope confirmed that CAFs remained 
attached, another 500 L of pre-warmed Trypsin-EDTA (0.25 % - 1mM) solution was added 
to each well for 1 minute to facilitate further detachment of CAFs by cutting away focal 
adhesion molecules enabling fibroblasts to anchor to the plate surface. Detached CAFs were 
collected in a 15 mL falcon tube and centrifuged for 7 minutes at 350 x G and then resuspended 
in 10 mL of growth medium (DMEM + 10 % FBS).  The 10 mL cell suspension was divided 
between two T-75 culture flasks and additional 5 mL of growth medium were added to each T-
75 flask with a total volume of 10 mL in each T-75 flask. The flask was then placed in cell 
culture incubator cabin at 37ºC in a 5 % CO2 humidified atmosphere for further proliferation 
of CAFs. Importantly, CAFs were incubated in serum-enriched medium which selectively 
promotes the expansion of fibroblasts while kills tumor cells.  
Passaging of fibroblasts 
The CAF cultures were observed with microscope every 24 hours, and the growth medium was 
changed every 2-3 days until the CAFs reached an optimal confluence between 80-90 %. This 
is important, since CAFs could die without space to grow. The morphology of fibroblasts can 
be described as an elongated shape, which are anchored-dependent. The result of this is that 
CAFs grow in a monolayer while they are attached to a solide or semi-solide substrate, as can 





Figure 4.2: Fibroblasts cultured in T-75 flask: 
Isolated fibroblasts from a patient with NSCLC 
with the characteristic elongated morphology 
attached to the surface in a monolayer. Pictures 
were taken with an inverted microscope connected 




The medium in T-75 flask was discarded when the fibroblasts reached the desired confluency 
of 80-90 % and replaced with Enzyme-Free detachment solution. This solution was kept in the 
flask for 10 minutes at 3 % O2 followed by adding Trypsin-EDTA (0.25 % - 1mM), which was  
kept in the flask for 2 minutes at 3 % O2 to desegregate CAFs clusters. Cells were collected in 
a 15 mL falcon tube and centrifuged at 350 x G for 10 minutes, supernatant discarded and pellet 
resuspended in 10 mL of growth medium and divided between two T-175 flasks with a total 
volume of 20 mL in each flask. Flasks were incubated at 37ºC in a 5 % CO2 humified 
atmosphere. To avoid extensive cell de-differentiation and potential induction of cell senescent 
by replication, all experiments were performed with cultures at passage 3-4 and no longer.  
Cryopreservation of primary tumor fibroblasts  
After 2nd passage of CAFs, the cells were used for further analyses or cryopreserved for use in 
later experiments. Cells destined for cryopreservation were first detached with Enzyme-Free 
solution and Trypsin-EDTA (0.25 % - 1mM) solution as previously described. Fibroblasts were 
then counted with a Neubauer Hemocytometry, centrifuged and cryopreserved at 80ºC in 
freezing medium consisting of DMEM with 10 % Dimethyl sulfoxide (DMSO) and 90 % FBS 
with 2-3x106 cells per mL per CryoTube. DMSO is one of the most preferred types of cryo-
protectants used in laboratories to prevent crystals to be formed during the freezing process of 
cells, which can damage the cell membrane. But, it is important to remember that DMSO can 
be toxic for cells when used at higher concentration (< 10 %) or if cells are exposed to DMSO 
for a longer time. Because of this, it is important to eliminate DMSO during the thawing process 
of cryo-preserved cells as soon as possible. When a CryoTube with cells was taken out from 
the freezer, the CryoTube was thawed between the hands fast to rapidly thaw the cells. The 




Fibroblasts were then centrifuged at 350 x G for 10 minutes, supernatant (containing freezing 
medium) discarded and pellet with fibroblasts resuspended in fresh growth medium followed 
by transferring cells to T-25 flask and place in cabin with 37ºC in a 5 % CO2 humidified 
atmosphere and incubated for 24 hours for attachment to the flask. The medium in flask was 
changed the next day with fresh DMEM medium to ensure that DMSO was completely 
removed. 
 
 Irradiation and preparation of cancer-associated fibroblasts 
conditioned medium and CAF co-culture assays 
4.4.1 General principles 
The condition medium (CM) from non-irradiated and irradiated CAF cultures were collected 
to investigate the paracrine effects on DCs. This medium contained different mediator 
substrates such as growth factors and cytokines secreted to the medium by CAFs which could 
affect different aspects of the immunological functions of DCs.  
4.4.2 General procedure 
When CAFs were passaged for the second time, cells were seeded at 4x105 cells per T-75 flask 
and then incubated for 24 hours for attachment to the surface at 37ºC in a 5 % CO2 humified 
atmosphere. After the initial attachment and when CAFs reached a confluence about 60-70 %, 
which took about 2 – 3 days to reach (dependent on donor), CAFs were irradiated. This was 
done with a Varian clinical linear-accelerator (Department of Irradiation Therapy in Tromsø 
University Hospital) (Figure 4.3), which produced the high-energy photons of 15 megavoltage 
(MV). Irradiation doses were delivered to CAFs either as three fraction dose of 6 Gy (24 hours 










T-flask were placed in the middle of the 20x20 cm field size and on top of three 10 mm thick 
water/tissue-equivalent Perspex-plates (30 mm in total), since photons produced at 15 MV 
reach the maximum dosage at 30 mm depth. The Gantry was positioned beneath the field and 
transported the beam from the linear-accelerator to the target.  
After irradiation, the T-flask with irradiated CAFs was placed back in incubator with 37ºC in a 
5 % CO2 humified atmosphere. CAFs cultured in T-flasks were used to generate CM, and it 
was important to prepare the CM to a solution as pure as possible without cells and other 
undesired components. This was done by collecting the 8 mL of medium 48h after irradiation 
followed by centrifugation and then filtering of CM. Medium from T-flask was collected in 15 
mL tubes and centrifuged at 350 x G for 10 minutes. Supernatant was poured in a new 15 mL 
tube subsequently and centrifuge again at 2000 x G for 10 minutes. CM was after the last 
centrifugation filtered in new 50 mL tube by using a 0.45 L filter, and by doing so eliminating 
the last remaining undesired components in the solution. CM was then either used immediately 
for experimental purposes or frozen down at -80ºC in 50 mL tube for later assays. Collected 
CM was normalized in relation to number of cells in T-flask. Density of cells in T-175 flask 
was approximately 450.000 cells/mL. Before analyzation, CAF-CM was thawed and vortex for 
30 seconds to ensure an adequate mixture of proteins in the suspension. It is important that 
control cells are not allowed to reach a state of high confluence, since this could result in cell 
death.  Non-irradiated CAFs could be frozen down after generation of CM and used for later 
experiments, but irradiated CAFs could not be used for further studies since they become 
senescence after irradiation.  
 
Figure 4.3: Varian clinical linear-
accelerator: T-flask with CAFs were 
placed on top of tissue-equivalent 
plates (30 mm depth) with gantry 





 Isolation of PBMCs 
Blood was collected from healthy donors at the Blood bank in Tromsø University hospital. 
Leukocyte-enriched blood (buffy coat) was centrifuge over LymphoprepTM density gradient 
medium to isolate PBMCs.  
4.5.1 General principles  
The LymphoprepTM method uses a density barrier as a mechanism to separate cells. Cells in the 
blood with a density higher than the medium (1.077 g/mL) goes through the barrier medium, 
such as erythrocytes and some polymorphonuclear cells. Other cells with a density lower than 
the medium, such as PBMCs, will remain in the interface after centrifugation  
4.5.2 General procedure 
Leucocyte-enriched blood was diluted 1:1 with PBS in T-75 flask to a total of 100 mL. Four 50 
mL tubes was filled with 15 mL LymphoprepTM and then 25 mL of the blood/PBS solution. 
This was done very carefully so the blood/PBS did not blend with the LymphoprepTM solution 
but maintain as a separate solution on top of LymphoprepTM. The four tubes was then centrifuge 
at 800 x G for 30 minutes at 20ºC without brake or acceleration to ensure no disturbance which 
could disrupt the separation of blood cells. After centrifugation, PBMCs could be seen as a 
white layer in the middle of tube between the top (plasma) and the bottom (erythrocytes), as 
seen in Figure 4.4. The white layer was collected from all four tubes with a Pasteur pipette and 
filled in a new 50 mL tube and centrifuge at 350 x G for 10 minutes at 20ºC. Supernatant was 
removed, and pellet resuspended in 50 mL PBS and 
centrifuge again at 350 x G for 10 minutes at 20ºC. 
Supernatant were discarded after the last step of 
centrifugation. PBMCs were either used in experiments 
after isolation or frozen for later use. PBMCs destined for 
freezing was first counted. Freezing medium consisting of 
90 % FBS and 10 % DMSO and was added to the tube 
with PBMCs according to how many cells that was 
counted. Approximately 5x107 cells was filled in each 
CryoTube (1 mL/tube) and the cells were cryopreserved at 
-80ºC until further use. Before utilization of frozen 
PBMCs, cells were rapidly thawed in 10 mL of complete 
Figure 4.4: PBMC isolation: Plasma 
can be seen on top and red blood cells 
in the bottom, while white blood cells 









medium consisting of RPMI-1640 culture medium supplemented with 10 % FBS and 1 % 
penicillin-streptomycin. 
 
 Isolation of CD14+ cells by immune-magnetic cell separation   
Human CD14+ monocytes were isolated from PBMCs with positive selection following the 
principle of magnetic activated cells sorting separation (MACS) (Miltenyi Biotec) by using 
anti-CD14-coated magnetic beads.  
4.6.1 General principle  
The principle of MACS separation is to isolate specific cell populations by particular surface 
antigens named cluster of differentiation (CD). Cells are incubated with magnetic microbeads 
that are coated with monoclonal antibodies against a particular CD molecule located on the 
surface of target cells. Solution with cells are then loaded into a MACS column and then placed 
in a strong magnetic field. Labelled cells with the magnetic microbeads are retained in the 
column as the solution passes, while other unlabeled cells in the solution passes through the 
column. When the column is removed from the magnetic field, cells remained attached to the 
column are eluted as the positively selected cell population.  
4.6.2 General procedure  
MACS buffer (0.2 % bovine serum albumin) was prepared by diluting MACS BSA Stock 
Solution 1:20 with autoMACSTM Rinsing Solution. MACS buffer was then kept on ice. PBMCs 
isolated from buffy coats was centrifuged at 300 x G for 10 minutes, supernatant discarded and 
pellet (with PBMCs) resuspended in 80 L of MACs buffer solution per 107 cells. After, 20 L 
of CD14 microbeads per 107 cells was added to the solution and mixed well before incubation 
of solution for 15 minutes at 4ºC in refrigerator. Following incubation, cells were washed with 
1-2 mL 0.2 % PBSA buffer and centrifuged at 300 x G for 10 minutes. Supernatant was 
discarded, and cells resuspended in 500 L MACS buffer. Cell suspension with beads was then 
loaded into a MACS LS-column which was attached to a strong magnetic field. This was 
followed by rinsing with 3 mL of MACS buffer into the column. This step was repeated three 
times. Column was then removed from the magnetic field, placed on top of 15 mL tube and 
then 5 mL of MACS buffer was loaded to the column. A plunger was placed on top of column 
and pushed carefully to ensure that all microbeads with attached CD14+ was removed from the 
column. Eluted cells was then washed by adding 10 mL of MACS buffer to tube and then 




mL of cell culture medium (RPMI-1640 culture medium with 10 % FBS and 1 % penicillin-
streptomycin). Monocytes were then counted and labeled with CD14-FITC antibodies for 
analyzation with Flow cytometry.  
4.6.3 DCs differentiation and maturation  
Isolated monocytes was first counted with Neubauer Hematocytometry to determine number of 
cells. Monocytes (6x106) were suspended in 18 mL of complete medium (RPMI-1640 culture 
medium with 10 % FBS, 1 % penicillin-streptomycin and pyruvate) and supplemented with 100 
ng/mL IL-4 and 100 ng/mL GM-CSF for differentiation of monocytes to iDCs. Monocytes 
were then transferred to 6-well tissue culture treated plates with 3x106 cells and 3 mL of 
complete medium in each well and incubated at 37ºC in 5 % CO2 humified atmosphere. After 
two days, a volume of 1.5 mL from each well was collected in the same 15 mL tube since all 
wells contained the same type of cells destined for the same purpose and centrifuged at 300 G 
x for 10 minutes. It is important to extract the cells carefully to avoid spontaneous activation of 
DCs. Supernatant was discarded and pellet with cells was resuspended in 9 mL of complete 
medium and 2-fold concentration of IL-4 and GM-CSF and transferred back to wells. The cells 
was ready to be used in assays after four more days of incubation. For maturation of mDCs, a 
volume of 1.5 mL is collected on day six of incubation. Cells are centrifuged at 300 x G for 10 
minutes and supernatant discarded. Pellet was resuspended in 9 mL of complete medium 
supplemented with 25 g/mL IL-6, 100 g/mL IL-1 25 g/mL TNF- and 2 g/mL PGE2 
and then transferred back to 6-well tissue culture plate incubated at 37ºC in 5 % CO2 humified 
atmosphere for 24 hours. An absolute cell count of mDCs was determined by flow cytometry 
via light scatter signals PI fluorescence.  
 
 Co-culture of CAFs with DCs 
Non-irradiated and irradiated CAFs was co-cultured with DCs to investigate the 
immunoregulatory effect CAFs may exert on DCs regarding cell-cell contact.  
Procedure: The process of co-culturing CAFs together with DCs was divided in two parts: 
- Isolation and culturing of DCs 
- Isolation, culture and irradiation of CAFs 
The procedure for isolation of CAFs are described in section 4.3 and the irradiation of CAFs in 




in section 4.6. The main difference between CAF-CM and CAF co-culture assays was that 
CAFs needed to be cultured in 24-well tissue culture plates before irradiation when used in co-
culture experiments. This is because CAFs become senescent after irradiation, which would 
make it difficult to detach the CAFs from flask and then make CAFs attach in plates used in 
co-culture with DCs. Non-irradiated and irradiated CAFs were co-cultured with DCs in a ration 
1:2, respectively, in all experiments regarding co-culture of CAFs and DCs.  
After 48 hours of co-culturing CAFs and DCs, DCs were centrifuge for 5 minutes at 300 x G 
and used in further experiments. Supernatant was transferred to new Eppendorf tube and 
centrifuge at 3000 x RPM for 10 minutes to exclude cell debris and frozen down at -80ºC for 
later use in ELISA experiments regarding the production of IL-10 and IL-12 by DCs. CAFs 
were attached to the 24-well tissue culture plates and this makes it possible and easy isolate the 
DCs after being co-cultured with CAF, since DCs are free in the solution enabling the cells for 
being extracted from the wells without CAFs.  
 
 Cell surface marker expression of DCs by flow cytometry  
Cell surface markers represents proteins exclusively expressed on the surface of cells and are 
regularly used as makers of specific cell types. For characterization of monocytes, iDCs and 
mDCs, a panel of different surface markers was used: CD14, CD1a, CD209, CD40, CD80, 
CD86 and HLA-DR. It was also of interest to investigate the change in expression of surface 
markers when DCs were cultured with non-irradiate or irradiated CAF-CM and DCs/CAFs co-
culture to compare the two conditions.  
4.8.1 General principle    
Flow cytometer is an instrument that can be used to analyze cells regarding size and complexity. 
Further, fluorochromes can be used to label specific membrane receptors and analyze receptor 
expression by flow cytometry. Sample solution with cells are placed inside the flow cytometer 
and injected into the instrument. A beam is adjusted allowing just one cell to pass through the 
laser at the time. When cells passes the laser, light is scattered (forward and side scatter) to a 
detector which gives information about the characteristics of cells passing the laser. Antibodies 
with attached fluorochrome has a wide fluorescence spectrum. An overlap between 
fluorochromes can occur when using more than one fluorochrome at the same time. This is 




calculated as a percentage to itself and this is a mathematical process were different 
multiparameter data is corrected for spectral overlap. Generated data can be plotted in a single 
dimension which produces one- or two-dimensional dot plots based on the intensity of 
fluorescence emitted from analyzed cells. Regions on these plots can be separated based on the 
fluorescence intensity and generate a series of subset extractions. This is called gating. The dots 
are often made on logarithmic scales. Because different fluorescent dyes emission spectra 
overlap, signals at the detectors have to be compensated electronically as well as 
computationally.  
Data analysis 
Data collected from flow cytometry experiments are analyzed with FlowJo on another computer 
than the actual flow cytometer process. Data is organized in “workspace” which allows for a 
hierarchical overview of the samples and the analyzation. Samples can be organized in panels 
regarding antibodies or tissue/cell type. 
4.8.2 General procedure  
Experiments regarding surface markers included monocytes, iDCs and  mDCs. Cell type used 
in experiments was first collected in a 1.5 mL Eppendorf tube and suspended with 100 L 
MACS buffer and 2 L of appropriate antibody (according to manufacture protocol). Solution 
was mixed thoroughly and incubated for 15 minutes in refrigerator (dark) at 4ºC. After the 15 
minutes, cells were washed two times by adding 1-2 mL of MACS buffer and centrifuged at 
1500 x RPM for 10 minutes to remove excessive antibodies in samples not bounded to cells. 
Pellet with cells was resuspended in 300 L of MACS buffer and analyzed by flow cytometry. 
PI was used to measure the live and dead cell ratio in the experiment.   
 
 Transwell migration assay  
Migration of mDCs was investigated under the influence of non-irradiated or irradiated CAF-
CM and in co-culture with CAFs. This was observed in the presence or absence of 
chemoattractant CCL-19 in a CCR7 chemotactic-dependent mechanism using Transwell 





4.9.1 General principles  
Transwell migration assay, also known as Boyden chamber, are often used to measure the 
movement and invasive capacity of different types of living cells towards a chemoattractant 
gradient. The chamber itself is comprised of a lower and an upper chamber separated by a thin 
membrane with pores, which allows cells of particular size to pass through (Figure 4.5). It is 
important to choose Transwell with pores that allows the target cell to pass through, but not 
allowing the passive migration of cells. Because of this, a membrane with smaller pores than 
target cells should be chosen. The chemoattractant is added to the solution in the lower chamber. 
After a certain time, cells in the lower chamber is collected and counted. One very important 
note in this experiment is that the number of cells placed in the upper chamber needs to be very 
accurate, since this number is used to evaluate how many cells that was able to migrate through 
the membrane and towards chemoattractant in lower chamber.  
Figure 4.5: Transwell migration assay: Cells are placed in the upper chamber (transwell insert) and 
was allowed to migrate towards the chemoattractant CCL19 in the lower chamber for 3 hours. Cell 
were afterwards counted to determine the migration capacity of cells.  
 
4.9.2 General procedure  
mDCs were incubated with CAFs in co-culture for 48 hours before used in migration assay. 
Then, mDCs was collected in 50 mL tubes and centrifugated at 300 x G for 10 minutes, 
supernatant collected for later experimental use and cells resuspended in RPMI 1640 with 10 
% FBS with a cell density of 5x105/mL. The upper chamber was filled with 200 L (1x105 
cells) of RPMI solution with cells. The lower compartment was filled with 600 L DMEM 
medium with 10 % FBS supplemented with Human CLL19 (MIP-3) (Miltenyi Biotec) with a 
concentration at 25 ng/mL. Transwell plates with cells were then incubated at 37ºC in 5 % CO2 
humified atmosphere for 3 hours. Cells were then collected from wells and counted with 
Neubauer Hemocytometry. 
mDCs used for CAF-CM migration experiments was also collected in 50 mL tubes and 




FBS to a cell density of 1x106/mL. In this assay, 100 L (1x105 cells) of RPMI solution with 
cells was filled in the upper chamber with 100 L of the appropriate CAF-CM. The lower 
chamber was filled with 300 L of DMEM medium with 10 % FBS, and 300 L of correct 
CAF-CM supplemented with Human CLL19 (MIP-3) (Miltenyi Biotec) with a concentration 
at 25 ng/mL. The remaining part of experiment was done as with co-culture migration. 
 
 Antigen uptake capacity of iDCs 
The pinocytotic antigen uptake capacity of iDCs was investigated after iDCs had been under 
the influence of non-irradiated or radiated CAF-CM or CAFs for 48 hours. Samples with cells 
was analyzed with flow cytometry to measure antigen uptake.  
4.10.1 General principles  
One of the most important features of iDCs is the ability to take up antigens through pinocytosis, 
which is a form of endocytosis. Internalized antigens are then presented on the surface through 
MHC class II molecules. In this assay, iDCs were first cultured with CAF-CM or co-cultured 
with CAFs. iDCs was afterwards collected and then treated with FITC-dextran to simulated 
antigens. Dextran was taken up by iDCs and the FITC molecule attached to dextran can then 
be recognized by analyzing cells with flow cytometry to determine the fluorescent emitted by 
DCs/FITC dextran uptake. 
4.10.2 General procedure  
A certain amount of DCs (1x105 cells) were incubated with 100 l of FITC-labeled dextran 
(MW 40,000 Sigma FD40S or equivalent – 1 mg/mL) in RPMI 1640 medium in 5 % CO2 at 
37ºC for 60 minutes. A control sample was kept on ice for 60 minutes to check for non-specific 
binding of FITC-dextran to cell surface. All samples were washed two times after 60 minutes 
of incubation to remove all unbound FITC-dextran in the solutions. This was done by centrifuge 
samples at 300 x G for 5 minutes in 4ºC with ice-cold PBS supplemented with 0.5 % BSA. 
Samples were kept on ice until cells were analyzed with flow cytometry. Uptake of FITC-
dextran was determined by measuring the mean fluorescence intensity (MFI) of FITC by flow 
cytometry and dead cells was excluded from the analysis by PI fluorescence. The specific 
antigen uptake of FITC-dextran by iDCs was calculated by subtracting the MFI of the control 





 T cell proliferation assay by mDCs 
In this assay, mDC ability to prime T cells was analyzed with flow cytometer after mDCs had 
being cultured with CAF-CM or in mDC/CAF co-culture. The T cell proliferation assay 
required both DCs and T cells. Human CD14+ monocytes were isolated from PBMCs by 
positive selection as described in section 4.6. Isolation of CD4+ T cells from PBMCs was done 
by the principles of magnetic activated cells sorting separation (MACS)(Miltenyi Biotec) with 
Naïve CD4+ T Cell Isolation Kit II, which is a negative selection. This is done by using a 
cocktail with biotin-conjugated monoclonal antibodies against CD8, CD14, CD15, CD16, 
CD19, CD25, CD34, CD36, CD45RO, CD56, CD123, TCR, HLA-DR and CD235a. This 
binds all unwanted cells to microbeads and column, while target cells are eluted from the 
column. mDCs are able to prime the CD4 T cells when cultured together by interactions through 
MHC class II molecules – TCR and co-stimulatory molecules CD80/CD86 – CD28.  
4.11.1 General principles   
mDCs ability to prime naïve CD4+ T cells were measured using CellTrace Violet solution (Life 
Technologies). This fluorescent dye is able to pass the cell membrane and bind to free amides 
inside cells. This provides a more stable and consistent signal compared to dyes binding to the 
cell membrane. CellTrace Violet acts without affecting the cells biology or proliferation. Cells 
of interest are incubated with dye, which enters cells and fluorescent intensity is measured. As 
the cells divides (proliferates), the dye becomes “diluted” amongst daughter cells, which results 
in less and less dye inside cells after each stage of cell division. Then, cells are analyzed again 
after a certain time with flow cytometry to measure the fluorescence intensity indicating 
proliferation. 
4.11.2 General procedure  
The isolation of CD14+ with positive selection and differentiation into iDCs and mDCs  are 
described in section 4.6. The isolation of CD4+ T Cells from PBMCs started with preparation 
of  MACS buffer containing phosphate-buffer saline (PBS), pH 7.2, 0.5 % bovine serum 
albumin (BSA), and 2 mM EDTA by diluting MACS BSA Stock Solution 1:20 with autoMACS 
Rinsing solution. PBMCs used for isolation of CD4+ T Cells was then centrifugated at 300 x G 
for 10 minutes, supernatant discarded and cells resuspended in 40 L of MACS buffer per 107 
of total cells. Then, 10 L of Naïve CD4+ T cell Biotin-Antibody Cocktail II per 107 cells was 
added and solution was mixed thoroughly and incubated for 5 minutes in refrigerator (2-8ºC). 




Cell MicroBead Cocktail II per 107 of total cells. Solution was well mixed and incubated in 
refrigerator (2-8ºC). Solution was then loaded to a MACS LS column attached to a strong 
magnetic field. Colum was first prepared by rinsing the column with 3 mL of MACS buffer. 
Cell suspension was then loaded in the LS column. Unwanted cells will bound to the magnetic 
column, while the enriched naïve CD4+ T cells will be in the flow-through that was collected. 
Column was washed by adding 3 mL of MACS buffer to the column to ensure removal of all 
enriched naïve CD4+ T cells from column.  
The purity of isolated enriched naïve CD4+ T cells was determined by labeling cells with i) 
CD4-PE or ii) CD45RO-APC and CD45RA-PE antibodies (Miltenyi Biotec) followed by 
analyzation with flow cytometry using MACSQuant Analyzer 10. Then, a total of 5x106 
purified naïve CD4+ T cells was suspended in 400 L PBS and labeled with 100 L of a 10 M 
CellTrace Violet solution (Life Technologies) for 5 minutes at room temperature. Cells were 
afterwards washed one time with 1 mL of ice-cold PBS supplemented with 1 % fetal calf serum 
and then three times with 2 mL MLR medium (RPMI 1640, 2 mM L-glutamine, non-essential 
amino acids, 0.1 mM sodium pyruvate, 5 % human antibody serum). In the last step, naïve 
CD4+ T cells were resuspended in MLR medium with a cell density of 5x105 cells/mL. mDCs 
were suspended in MLR medium as well at a cell density of 1x106 cells/mL and diluted 1:2. 
The different dilutions of cells were transferred to 96 well plate with 100 L of diluted solution 
in each well. Then, solution with naïve CD4+ T cells were added to wells with 100 L of 
solution in each well. Plates with cells were incubated for 7 days at 37ºC, 5 % CO2. The 
proliferation of CD4+ T cells was determined by measuring dilution of cell-associated 
CellTrace Violet by flow cytometry. Dead cells and debris was excluded from the analysis by 
scatter signals and PI fluorescence. As the T cells proliferate, the intensity of fluorescence 









 Enzyme linked immunosorbent assays (ELISA)  
Enzyme linked immunosorbent assay (ELISA) was done to quantify the production of IL-10 
and IL-12 by mDCs. 
4.12.1 General principle  
The sandwich ELISA is a method used to quantify antigens between two layers of different 
antibodies (i.e. capture and detection antibody). Antigen in sample needs to contain a minimum 
of two different antigenic epitopes, which are capable to bind antibody, because at least two 
antibodies acts in the sandwich. Either monoclonal or polyclonal antibodies are used in 
Sandwich ELISA as capture and detection antibodies. Monoclonal antibodies  can recognize 
one single epitope which allows accurate detection and quantification of small differences in 
antigen. A polyclonal is most often used as the capture antibody to pull down as much of the 
antigen as possible, and the capturing antigen is attached to the surface of the 96-well plate used 
in ELISA. Streptavidin is used to detect antigens and binds to detector antibodies that 
conjugates with an enzyme named Horseradish Peroxidase (HRP) which is detected by the 
substrate Tetramethylbenzidine (TMB). The enzyme – substrate complex converts the substrate 
to a colored product in the reaction, which means that ELISAs uses a colorimetric substrate as 
a reporter for detection. One advantage of using Sandwich ELISA is that the sample does not 
need to be purified before the analysis. The method is very sensitive and can be 2 to 5 times 
more sensitive compared to direct or indirect ELISA. The principle behind Sandwich ELISA 
can be seen in Figure 4.6. 
 
Figure 4.6: Principle of Sandwich ELISA: Plate with wells are coated with capture antibody. Wells 
are washed before samples are added, which binds to capture antibodies. The wells are then washed 
again followed by adding of detection antibodies. Wells are washed to remove all unbound antibodies 




4.12.2 General procedure 
A total of four ELISAs was done in the study to determine the concentration of IL-10 and IL-
12 produced by mDCs in the presence of CAF-CM or in mDC/CAF co-culture. Concentrations 
of IL-10 and IL-12 was determined from supernatant obtained from experiments involving 
mDCs cultured for 48 hours with either CAF-CM or in co-culture with CAFs. The concentration 
was determined by using Human IL-10 DuoSet® and Human IL-12 DuoSet® ELISA kits. The 
sample for IL-12 detection was diluted 1:4 with Reagent dilution, while sample for IL-10 was 
not diluted. Kits were used in duplicates as according to product protocol. Reading of plates 
used in ELISA was recorded through a Multiskan Ascent microplate reader at a wavelength of 
450 nm. Ascent Software was used for the construction of standard curves and for the 
determination of protein concentrations in the different samples. Curve fitting was done as 
described by the manufacture instruction with a four – parameter logistic algorithm.  
All reagents and solutions used in the experiment was purchased individually and reconstituted 
according to the instructions. Standard curves were established by two-fold serial dilutions and 
run in triplicates in all ELISA test. Blank was also in triplicates. The experimental control 
contained iDCs and mDCs.  
 
 Statistical analysis 
The results from all experiments represents the average measurements from all donors with 
standard deviations (S.D) and displayed as a fold of DCs control. Regarding the experiments 
with ELISA, only readings above the detection limit of the assays are included in the results. 
Data from experiments was analyzed using paired Student`s T-test. And P values < 0.05 was 
regarded as statistically significant. Graph pad prism 7.00 was used for analyzation and 




































 Isolation of primary cancer-associated fibroblasts and radiation 
protocols 
CAFs were isolated from specimens resected from patients with non-small-cell lung carcinoma. 
The purity of isolated and culture expanded cells was determined by linage-specific markers 
including −SMA and FAP-1 (not shown). Isolation of CAFs was followed by irradiation with 
clinical linear accelerator according to protocols established by Hellevik et al [168] to generate 
CAF-CM and CAFs for use in co-culture experiments with DCs. Figure 5.1 represents CAFs 
morphology before and after irradiated with 3x6 Gy and 1x18 Gy. CAFs acquired a flat and 
enlarge morphology after irradiation which could be an indicative of cell growth arrest.  
 
Figure 5.1: Irradiation of cancer-associated fibroblasts: CAFs isolated from patients with NCSLS and 
culture-expanded for 3 passages were exposed to two different regiments of irradiation: medium-dose 
fractioned irradiation (3x6 Gy) and single high-dose irradiation (1x18 Gy) to produce both CAF-CM 










 Isolation of CD14+ monocytes and differentiation into immature and 
mature DCs 
The result from isolation of monocytes and generation of DCs can be seen in Figure 5.2. 
Isolated monocytes can be observed with an irregular morphology with a relatively small cell 
size. Differentiated iDCs was seen with much larger cells size compared to monocytes and had 
more distinct spherical morphology. The following maturation of iDCs generated mDCs with 
dendritic structures.  
 
 
Figure 5.2: Generation of monocytes, iDCs and mDCs: Monocytes were isolated from PBMCs and 
differentiated into iDCs by culturing monocytes with cocktail containing GM-CSF and IL-4. For 
generation of mDCs, iDCs were incubated for 48 hours with a cytokine cocktail comprising IL-6, TNF-
, PGE2 and IL-1. 
 
 
 Gating strategy for flow cytometry analyses 
DCs transformation was checked by surface expression of known DC differentiation markers. 
An array of surface markers was used, which included CD14, CD1a, CD209, CD80, CD86, 
CD40 and HLA-DR (MHC class II). For determination of different cell populations and the 
assortment of antibodies used as surface markers, it was important to use the correct gating 
when applying samples to flow cytometry. The gating strategy can be seen in Figure 5.3. A) 
After isolation of CD14+ cells by antibody-coated magnetic beads from the total pull of PBMCs, 
the population of DCs was selected based on the forward scatter (size) and side scatter 
(complexity), B) Single populations of cells was selected C) All CD14- cells were excluded, D) 
For monocytes, cells of interest expressed CD1ahigh/CD209high and target cells as can be seen 
in the upper right corner, E) iDCs express lower amount of HLA-DR and CD80 indicated with 
red, compared to mDCs with high expression of HLA-DR and CD80 indicated with blue. 
6 days 2 days 
Monocytes CD14+                              Monocyte-derived immature DCs                     Monocyte-derived mature DCs 
IL-4 + GM-CSF IL-6 + TNF- 






Figure 5.3: Gating strategy: A) The population of DCs were gated and can be observed as large cells 
compared to lymphocytes and monocytes, B) Single population of cells was selected while cluster of 
cells was excluded, C) All CD14- cells was excluded, D) Cells of interest expressed CD1ahigh/CD209high, 










Specific antibodies were used to detect the variety of surface markers included in the study. 
Unstained cells were used to establish cut-off of cellular autofluorescence, and each of the 
antibodies was gated. Figure 5.4 is an example of the gating strategy for CD14, CD1a and 
CD209. The expression of CD14 amongst iDCs are 72.5 %, as compared to 2.75 % for mDCs 
who have lost almost all expression of CD14. The expression of CD1a is higher for iDCs with 
72.5 %, while expression is 58 % for mDCs. The same is the case for surface marker CD209 
were iDCs expression is measured to 72.8 % compared to mDCs with 53.3 %.  
 
 
Figure 5.4: Gating strategy: iDCs and mDCs generated from monocytes were incubated with antibodies 
specific for CD14, CD1a and CD209 followed by analysis with flow cytometry. This provided 
information about level of expression of the different markers, helping to identify different phenotypes 
of DCs. This was later used to observe if CAFs in either CAF-CM or co-culture experiments modulate 





 CAFs regulate monocyte-to-dendritic cell transdifferentiation 
First, we wanted to investigate the expression of surface markers related to the differentiation 
from monocytes to iDCs, and if this transition was influenced by CAFs. It was also an objective 
to rule out if CAF-mediated effects were dependent on paracrine signaling or cell-cell 
interactions and if irradiation induced any alterations on CAFs modulating affect. We could 
first observe from the result in Figure 5.5 that cytokine cocktail was working as expected, since 
monocyte marker CD14 was downregulated in transformed DCs, whereas iDCs markers CD1a 
and CD209 were elevated. Further, CAFs (both CM and co-cultures) were able to block 
phenotypic transformation of monocytes. DCs cultured with non-irradiated CAFs in co-culture 
showed increased expression of CD14 (almost 50%), reduced 80 % of the expression of 
functional marker CD1a and around 45 % for CD209, compared with controls. However, CAFs 
induce immunoregulating effect on the expression of surface markers varies. The strongest 
effects on DCs transdifferentiation were achieved during co-culture conditions, those 
suggesting that at least some of the CAF-mediated effects are exerted via cell-cell interactions. 
Irradiation neither enhance or suppress expression when comparing with non-irradiated CAFs, 
except CD1a expression in CAF-CM experiments. CAFs irradiated 3x6 Gy lose to some extent 

















Figure 5.5: Monocytes to iDCs differentiation markers (CD14, CD1a and CD209): Monocytes were 
cultured with cocktail containing IL-4 + GM-CSF for differentiation into iDCs. In addition, non-
irradiated and irradiated CAFs was used to investigate CAFs immunoregulatory role in the 
differentiation. Expression of surface markers was analyzed with flow cytometer and results represents 
mean value obtained from four different CAF donors. Data were calculated by using Student`s T-test 
and p-value (*<0.05) was calculated between controls and non-irradiated and irradiated CAFs. 
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 CAFs regulate immature-to-mature dendritic cell differentiation  
CAFs effects were further investigated with the same surface markers in experiments regarding 
maturation of DCs. The results from these experiments are shown in Figure 5.6, and the data 
suggest that CAFs could utilize paracrine signaling and direct cell-cell contact communication 
for their control of DCs maturation. The experimental data indicate that CAFs hinder DCs 
maturation as the expression levels of CD1a are comparable to iDCs (increased 10 % for CAF-
CM and 15 % for co-culture). Radiation exposure was able to partly revert CAF-mediated 
effects on CD14 expression in experiments with CAF-CM. Whilst CAF-CM modulates an 
upregulation of the expression of CD14 with approximately 15 %, irradiation of CAFs with 
both 3x6 Gy and 1x18 Gy reverted the modulating effect of CAFs and mDCs express the same 
level of CD14 as control with a significant result (p=<0.05). Same tendencies were observed in 






















Figure 5.6: iDCs into mDCs differentiation markers (CD14, CD1a and CD209): iDCs were incubated 
with cocktail containing IL-6 + IL-1 + TNF- + PGE2 for maturation into mDCs. Non-irradiated and 
irradiated CAFs were used to observe CAFs modulation regarding maturation. Expression of surface 
markers was evaluated with flow cytometry and results represents mean value obtained from four 
different CAF donors. Data was calculated with Student`s T-test and p-value (*<0.05) was calculated 
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 CAFs affect expression of maturation markers CD80 and CD86 
The expression of co-stimulatory receptors normally expressed in mature DCs was studied.  
Here, we used surface markers CD80, CD86, CD40 and HLA-DR, and CAFs modulating effect 
on the expression of these surface markers can be seen in Figure 5.7. We could observe that 
CAF-CM exerted stronger suppressive effects on the expression of CD80 and CD86 compared 
co-culture conditions. Fractioned radiation reverted the immunoregulatory effect of CAFs 
supernatants with significant result (p<0.05). Very small differences in the expression of CD80 
and CD80 could be observed when DCs were co-cultured with irradiated and non-irradiated 
CAFs, Co-cultures with irradiated CAFs resulted in enhanced expression of CD80 by DCs with 
statistically significant result (p<0.05). 
 
 
Figure 5.7: iDCs into mDCs maturation markers (CD80 and CD86): iDCs were cultured with cocktail 
containing IL-6 + IL-1 + TNF- + PGE2 for maturation into mDCs. Furthermore, non-irradiated and 
irradiated CAFs were used to investigate CAFs immunomodulating function regarding functional 
marker expression. The expression of surface markers was analyzed with flow cytometry and results 
represents mean value obtained from four different CAF donors. Data was calculated with Student`s T-
test (p-value = *<0.05). Result is presented as mean fluorescence intensity (MFI). 
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 CAFs regulate expression of CD40 and HLA-DR 
We also wanted to investigate the possible modulation of surface markers CD40 and HLA-DR. 
The data from experiments can be seen in Figure 5.8 and indicates that both CAF-CM and 
CAFs in co-culture with DCs are capable to induce changes in the expression of maturation 
markers. Same tendencies can be seen in all conditions, were CAFs blocks expression of both 
CD40 and HLA-DR through paracrine signaling and possible cell-cell mediated interactions, 
resulting in education of mDCs towards iDCs phenotype. Fractioned radiation hinder CAF-
mediated immunosuppressive effects on DCs maturation, whereas CAF irradiated at a single 
high-dose behave in a similar was as non-irradiated CAFs.  
 
Figure 5.8: iDCs into mDCs maturation markers (CD40 and HLA-DR): iDCs were cultured with 
cocktail IL-6 + IL-1 + TNF- + PGE2 to stimulate DCs maturation. In addition, non-irradiated and 
irradiated CAFs were used to investigate CAF immunoregulatory role in the maturation. Expression of 
functional markers was analyzed with flow cytometry and results represents mean value obtained from 
four different CAF donors. Data was calculated with Student`s T-test (p-value = *<0.05) and result is 
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 CAFs modulate DCs immune functions  
In previous experiments, the focus was put on phenotypic markers that are used to distinguish 
the maturation state of DCs. These results demonstrated that CAFs may use paracrine signaling 
and cell-cell interactions to influence DCs phenotype. We followed these experiments by 
analyzing CAF-effects on DCs function. For this, we used three hallmark functions associated 
to DCs; antigen uptake, cell migration and priming of naïve CD4+ cells. 
5.8.1 Antigen uptake capacity in iDCs is suppressed by CAFs 
The result from antigen uptake can be seen in Figure 5.9 and illustrates uptake of FITC-dextran 
over a time period of 60 minutes. As expected, controls demonstrate that mDCs display low 
uptake of dextran compared to iDCs. Data indicates that non-irradiated CAF-CM blocks antigen 
uptake for iDCs, and the effect is reverted with fractioned irradiation of CAFs but not with 
single high-dose. CAFs in co-culture has marginal suppressive function on antigen uptake by 




Figure 5.9: Antigen uptake of iDCs: Untreated mDCs and iDCs were used as controls in antigen uptake 
for comparison. Further, iDCs were cultured with non-irradiated and irradiated CAFs to investigate 
CAFs modulation of iDCs uptake of FITC-dextran. The result was collected by flow cytometry and 
results represents mean value obtained from four different CAF donors. Data was calculated by using 
Student`s T-test and p-value (*p<0.05) was calculated between controls and non-irradiated and 



























5.8.2 DCs migration capacity is reduced by CAFs 
Result from migration assay can be seen in Figure 5.10, and controls indicates that iDCs have 
low migratory capacity compare to mDCs as expected. But when mDCs have been subjected 
to CAF-CM or CAFs themselves before used in the migration assay, the migratory effects 
(almost 50%) have been lost. Fractioned irradiation of CAFs curtails the effect observed by 
non-irradiated CAF-CM on the migration capacity of mDCs, but not if CAFs were irradiated 
with single high-dose irradiation. However, in co-culture experiments radiation of CAFs blocks 




Figure 5.10: Effects of CAFs on the migration capacity of mDCs: iDCs and mDCs was used in control 
to compare migration capacity. Further, mDCs was cultured with non-irradiated and irradiated CAFs 
to investigate CAFs immunoregulatory function regarding mDCs migration towards chemoattractant 
CCL19. Migrated cells were counted, and results represents mean value obtained from four different 
CAF donors. For analyses, pair comparisons were done among all experimental groups. Results are 



























5.8.3 CAFs reduces mDCs priming capacity of naïve CD4+ T cells  
The next step in our investigation of CAFs immunoregulatory role included mDCs priming of 
naïve CD4+ T cells, causing proliferation of T cells. For the proliferating experiments, isolated 
CD4+ T cells were incubated with mDCs in a ration 2:1, respectively. To measure the 
proliferation, T cells were labeled with CellTrace CFSE. Results are shown in Figure 5.11 and 
controls demonstrate minimal T cell priming by iDCs while mDCs display high priming 
capability. The experiments indicates that DCs ability to prime CD4 T cells is suppressed in 
CAF-CM and co-culture experiments. A loss of approximately 10 % of  priming ability for 
mDCs can be seen with CAF-CM, and for experiments regarding co-culture experiments the 
number is approximately 20 %. The result also demonstrated that CAFs subjected to either 
medium-dose fractioned (3x6 Gy) or single high-dose (1x18 Gy) did not affect CAFs 





Figure 5.11: Irradiated and non-irradiated CAFs equally reduce the T cell priming abilities of 
matured DCs: Untreated iDCs and mDCs was used as control for priming of naïve CD4+ T cells for 
comparison. mDCs was in addition cultured with non-irradiated and irradiated CAFs to observe CAFs 
modulation of mDCs priming ability. The results was evaluated with flow cytometry and results 
represents mean value obtained from four different CAF donors. Data was calculated with Student`s T-
test and p-value (*<0.05) was calculated between controls and non-irradiated and irradiated CAFs. 





























 Cytokine production by DCs is affected by CAFs  
We continued our investigation of CAFs immunosuppressive role towards DCs by 
determination of cytokine profile from DCs under the influence of CAFs. The result from IL-
12 measurements with ELISA can be seen in Figure 5.12. and the experiment with CAF-CM 
demonstrated that non-irradiated CAFs blocks the production of IL-12 by DCs, while 
irradiation of CAFs reverted the modulating function of CAFs to some extent. On the contrary, 
experiments with DCs in co-culture with CAFs resulted in an increase of DCs production of 




Figure 5.12: IL-12 production by mDCs is affected by CAFs: Supernatant collected from co-culture 
experiments with non-irradiated and irradiated CAFs were used to measure production of IL-12 by 
mDCs. In addition, iDCs supernatant was used as control for comparison. Results were analyzed with 
flow cytometry and results represents mean value obtained from four different CAF donors. Data was 
calculated by Student`s T-test and p-value (*<0.05) was calculated between controls and non-irradiated 
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We also wanted to investigate IL-10 production by DCs under the influence of CAFs. The result 
can be seen in Figure 5.13, and the data indicates low concentration of IL-10 produced by DC 
under normal conditions. Our data suggest again two very different scenarios for CAF-CM and 
co-culture experiments. Mature DCs express lower levels of IL-10 than immature DCs. 
Conditioned medium from all CAF groups have no effect on IL-10 secretion. On the other hand, 
in co-culture settings, irradiated and non-irradiated CAFs promote IL-10 secretion by mDCs It 
has to be taken in consideration that measured level of IL-10 with Elisa was generally very low.  
 
 
Figure 5.13: CAFs regulate production of IL-10 by mDCs: Supernatant gathered from co-culture 
experiments with non-irradiated and irradiated CAFs were used to measure IL-10 production by mDCs. 
iDCs were also used as control for comparison. Results were analyzed with flow cytometer and results 
represents mean value obtained from four different CAF donors. Data was analyzed with Student`s T-
test and p-value (*<0.05) was calculated between controls and non-irradiated CAFs. Results are 
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6 Discussion  
It is generally believed that CAFs have an important role in the modulation of an anti-tumor 
immune response displayed in the tumor microenvironment [169]. Besides, DCs play a critical 
role in generating anti-tumor CD8 T cell immunity [170, 171]. Ionizing irradiation has been 
demonstrated to induce changes in the tumor stroma such as e.g., DNA damage, hypoxia, 
inflammation, cellular stress and cellular senescence [172]. Evidence from in vitro studies has 
indicated that CAFs is a radioresistant cell type and may survive high ablative doses of ionizing 
radiation [173]. However, radiation doses above 12 Gy induce permanent DNA damage 
responses and the concomitant development of irreversible cellular senescence [168]. 
Additionally, high radiation doses are able to influence the secretory profile of CAFs, thus 
affecting potential CAF-mediated paracrine signaling. However, little is known about how 
ionizing radiation could modulate CAF-mediated immunoregulatory effects on DCs. In this 
study, we showed that:  
- CAFs down-regulate the expression of maturation markers on DCs trough paracrine 
signals and cell contact-dependent mechanisms  
- DCs immune functions are curtailed when cultured with CAFs or CAF-CM   
- CAFs down-regulate the expression of IL-12 in CAF-CM experiments, while the 
expression of IL-12 is upregulated in co-culture 
- The secretion of IL-10 is enhanced by CAFs in co-culture 
- Fractioned medium-high doses and to a lesser extent single high-dose irradiation can 
revert some of the CAF-mediated effects exerted on DCs 
Tumor infiltrating immune cells are exposed to different factors in TME that may regulate their 
function [174]. CAFs are known for contributing to create this immunosuppressive 
environment, and inflammatory cytokines in CAFs secretory profile includes TGF-beta, IL-10, 
HGF and VEGF [91, 175].  
 
We used different in vitro assays to characterize the influence of CAFs on DCs phenotype and 
function. Initially, we checked the influence of CAFs on DCs differentiation and maturation. 
One of the main differentiation markers for myeloid lineage cells is CD14, which is a protein 
crucial for immune recognition [176]. Monocytes are characterized by high expression of 
CD14, while iDCs and mDCs lose the expression of CD14 during differentiation and 




expressed on iDCs related to antigen uptake [177-179]. Our controls showed that isolated 
monocytes displayed high expression of CD14 and low expression of CD1a and CD209 as 
expected. Further, iDCs had lower expression of CD14 and higher expression of both CD1a 
and CD209, which confirms the transdifferentiation of monocytes into iDCs. Our findings 
indicated that CAFs suppress to a large extent monocyte – iDCs conversion as showed by 
expression of differentiation markers.   
 
Further, we analyzed if CAFs could block the maturation of DCs. iDCs are characterized by 
moderate expression of CD14 and high expression of CD1a and CD209, while mDCs have lost 
almost all expression of CD14 and shows moderate expression of CD1a and CD209. iDCs 
stimulated with the cytokine cocktail and incubate in the presence of CAF-CM shows enhanced  
expression of all surface markers with significant result for CD14. We also assessed CAF-
mediated regulation of DCs co-stimulatory molecules CD80, CD86, CD40 and HLA-DR 
typically expressed on mDCs and used in communication with naïve CD4+ T cells. We showed 
that CAFs restrained the maturation of iDCs significantly by down-regulation of CD80 and 
CD86. Our findings demonstrated that CAFs suppress the expression of co-stimulatory 
molecules CD80 and CD86 mainly through paracrine signaling. For the expression of CD40 
and HLA-DR, we could observe that CAFs suppressed the expression of both surface receptors 
in CAF-CM and co-culture experiments.  
The biology of DCs can possibly be altered by the secretome of CAFs. Studies have 
demonstrated that IL-10 can inhibit the maturation of iDCs, resulting in downregulated 
expression of CD80 and CD86 [180]. Corinti et al (2001) also provided evidence that culturing 
DCs with IL-10 blocked the maturation of iDCs [181] supported by studies were tumor-derived 
IL-10 is correlated with accumulating DCs with immature phenotype [182]. Wang et al (1995) 
showed that IL-10 has an inhibitory effect on the NF-B pathway [183],  and other studies have 
demonstrate that blocking of NF-B signaling during DCs differentiation results in anergy and 
regulatory T cell activity [184]. There is evidence showing that TGF- could suppress the 
maturation process [185, 186]. Mou et al demonstrated by using a mouse model that DCs 
maturation is restricted by TGF- and also downregulate toll-like receptors [187]. VEGF may 
be involved in the suppression of maturation as well. Study shows that VEGF binds to Flt-1 
receptor and inhibits the NF-B pathway by decreasing the specific DNA binding of NF-B 
[188]. This demonstrates that CAF-derived inflammatory molecules could have profound 




For all assays regarding CAFs modulating effect on DCs functionality, we used both iDCs and 
mDCs in controls. iDCs are specialized cells for antigen uptake, while mDCs have a phenotype 
participates in migration to lymph nodes and for priming of naïve CD4+ T cells. Our controls 
demonstrated that iDCs antigen capacity was much higher than mDCs while mDCs displayed 
better migratory and T cell priming ability compared to iDCs. The effect of CAFs modulation 
on DCs functions was in some cases quite high. For antigen uptake, we could observe that CAFs 
exerted their effect mostly through secreted molecules as was demonstrated in the experiments 
using CAF-CM were the antigen uptake was reduced compared to controls. In migration 
experiments, both CAF-CM and co-culture conditions blocked approximately 50 % of the 
migratory capacity of mDCs. There are some factors that are known to reduce the migratory 
capacity of DCs, such as IL-6, TGF-, and VEGF, by changing the expression of chemokine 
receptors [189]. Other studies have investigated the correlation between TGF- and the effect 
upon DCs migration, which demonstrated that TGF- reduces the migratory capacity of mDCs 
in vivo [190, 191]. As for priming of naïve CD4+ T cells, CAFs demonstrated to suppress T cell 
priming within 10 % in cells cultured with CAF-CM and 15 % in co-culture. Yang and Lattime 
(2003) demonstrated that IL-10 could suppress DCs priming of CD4+ T cells in a mouse bladder 
carcinoma model [192]. These findings further support that CAF-secrete signal molecules 
contributes to suppress DCs function. 
 
DCs are in addition to be important cells for the initiation of adaptive immune responses also 
crucial for maintaining immune homeostasis and can be considerate as gatekeepers of the 
immune system [193]. IL-10 is a pleiotropic cytokine with anti-inflammatory properties and 
can thereby suppress immune responses [194]. IL-10 is known to have immunosuppressive 
functions and can mediate inactivity of CD4+ T cells in addition to reduce NK cells expression 
of inflammatory cytokines but stimulate proliferation of mature CD8+ T cells in vivo [195]. The 
role of IL-10 in relation to cancer is controversial, since some studies suggest that IL-10 has a 
tumor-promoting role [196] while other studies indicates that IL-10 has an anti-tumor activity 
[197]. But it is generally believed that IL-10 is tumor-promoting, and an elevated level of IL-
10 is usually correlated with poor prognosis for patients [198]. We wanted to investigate if 
CAFs could be responsible for the education of DCs towards IL-10 secreting DCs, which is an 
indication of a tolerogenic phenotype of DCs [199]. In fact, for experiments regarding paracrine 




For DC/CAF co-culture experiments we could see that CAFs induced upregulation of IL-10 in 
DCs. 
 
On the other hand, IL-12 is a pleiotropic, anti-inflammatory cytokine with pivotal immune-
modulatory roles with important anti-tumor activity. IL-12 is known for inducing proliferation 
of NK cells and T cells, which results in the production of cytokines such as IFN-. IL-12 also 
activates STAT4, which improves the generation and activity of CTLs [200]. One of the main 
sources for IL-12 are antigen presenting cells, such as DCs [201]. We speculated that CAFs 
might downregulate the production of IL-12, due to the anti-tumoral nature of IL-12 [202]. We 
showed that CAFs blocks the secretion of IL-12 by DCs cultured with CAF-CM as we expected. 
But for the experiments in co-culture, we could see that CAFs actually increased the expression 
of IL-12. A possible explanation for the opposite result can be explained by CD40 – CD40L 
interactions in co-culture conditions, which activates TRAF6 and induces activation of p38 
Kinase (MAPK9) and JNK (Jun Kinase) and upregulation of IL-12 by DCs. This was 
demonstrated in knockout mice that were unable to produce IL-12 in response to CD40L [138]. 
Another study demonstrated that both CD40L, mRNA and protein is produced by lung 
fibroblasts [203], which could explain why we could see increased expression of IL-12 by DCs 
in co-culture experiments due to the interaction of DCs surface markers CD40 and CD40L on 
fibroblasts.  
 
Furthermore, we evaluated the effect of irradiation, applied as fractioned medium-high dose 
(3x6 Gy) or single high-dose (1x18 Gy) on CAF-mediated tolerogenicity on DCs. In this study, 
we observed some moderate changes in the expression of surface markers after CAFs had been 
irradiated with a few remarks. In the differentiation of monocytes into iDCs, we could observe 
a reverted expression of CD1a after CAFs had been irradiated with 3x6 Gy, although the result 
was not significant. And for CD14 in maturation from iDCs into mDCs, we could observe that 
both regiments of irradiation had a significant suppressive effect on the expression  of CD14. 
As for co-stimulatory molecules CD80 and CD86, the expression was reverted after CAFs had 
been irradiated with 3x6 Gy with a significant result for both receptors in CAF-CM 
experiments. In vivo studies have demonstrated that irradiation of mice with medium-dose 
radiation enhance expression of CD80 and CD86 on DCs [204]. Same tendencies were 




were irradiation with 3x6 Gy blocks or eliminate the immunosuppressive effects exerted by 
CAFs on DCs maturation. 
 
In functional studies, we could see that irradiation of CAFs with 3x6 Gy improved the 
functionality of DCs in antigen uptake and migration with significant results. For priming 
assays, CAFs irradiation did not alter DCs priming of CD4+ T cells. On the contrary, Lee et al. 
demonstrated using an in vivo melanoma model that ablative irradiation with single high-dose 
of 20 Gy improved T cell proliferation in draining lymph nodes [205]. This could demonstrate 
that irradiation in vivo may have different effect on the priming of CD4+ T cells compared with 
in vitro model as we used in our experiments.  
 
DCs can due to their highly functional plasticity exert both immunogenic and tolerogenic 
immune responses [206]. DCs with tolerogenic phenotype and functions are known as 
tolerogenic DCs (tolDCs) or semi-mature DCs [207]. DCs can be differentiated into tolDCs in 
vitro with growth factors such as IL-10, TGF- and HGF. CAFs secrete these inflammatory 
cytokines, suggesting that CAFs can polarize DCs to become tolerogenic through pathways 
related to these signal molecules [105, 208, 209]. But the mechanisms for inducing DCs to 
become immunogenic or tolerogenic in vivo are not fully understood [210]. TolDCs are able to 
induce T cell tolerance through different approaches, including production of anti-
inflammatory cytokines, induction of T cell anergy, suppress effector T cells, generation of 
Tregs through de novo differentiation or activating already existing Tregs [211]. TolDCs can 
be characterized by low expression of functional markers such as CD80, CD86, CD40 and 
MHC complexes [212, 213] and can resemble iDCs with poor immunogenic functions [214]. 
In this study, we could observe that there exists a communication between CAFs and DCs. 
From these findings we can further interpret that CAFs may educate DCs to become tolerogenic 
through CAFs secretome, but possibly also by cell-contact mechanisms on the foundation that 
CAFs are able to down-regulate the expression of functional markers for DCs and also the 
functionality of DCs. Elevated production of IL-10 by DCs could also indicate that CAFs 
induce tolDCs phenotype, but it has to be taken into consideration that the measured 
concentration of IL-10 from experiments was quite low and that in vitro experiments may be 





Our group is continuing its research to determine regulatory factors secreted by CAFs that are 
involved in the modulation of different immune cells, including DCs. In this future research, 
exosome-related experiments is one of the focus areas. This includes isolation of exosomes 
from CAFs by ultracentrifugation followed by in vitro assays including surface markers and 
functional experiments for trying to determine if CAF-secreted exosomes or other soluble 
factors contributes to the immunoregulatory role that CAFs play. At this point, the results are 
still inconclusive, but we were able to observe tendencies from the results, suggesting that CAF-
secreted exosomes may contribute to induce immunosuppressive effects.   
 
Here in this study, we demonstrated that both fractioned medium-high dose and high-dose 
irradiation induce changes in CAFs resulting in altered immunosuppressive effect towards DCs 
regarding expression of functional markers, cytokine production and functionality. However, 
our data suggests that fractioned delivered irradiation promotes more favorable effects on CAFs 
immunomodulation regarding DCs compared to single-high dose irradiation. These results 
demonstrate that fractioned radiotherapy could be beneficial and clinically relevant for 
















7 Conclusions  
In this study, we have demonstrated that there is a cross-communication between CAFs isolated 
from patients with NSCLC and DCs isolated from peripheral blood of healthy donors. A few 
main observations can be highlighted from this study: (1) Our results demonstrated that CAFs 
in experiments with CAF-CM and in co-culture promotes changes in DCs causing down-
regulation of certain functional markers, (2) CAFs suppressed the function of DCs through 
secretion of molecules and cell-cell interactions, (3) Both fractioned medium-high dose (3x6 
Gy) and single high-dose (1x18 Gy) irradiation of CAFs induces changes which in some cases 
lead to normalization of surface marker expression and improved the function of DCs.  
 
The immune system is crucial for restraining cancer growth, but as it turns out, tumors are able 
to highjack the immune system and alter their functions. This can reduce normal immune cell 
functions, but also promote immune cells towards protumorigenic machinery that leads to 
tumor progression. Several approaches have been taken trying to figure out how to overcome 
the challenges correlated with cancer research due to the genetic instability of cancer. Cancer 
research has provided knowledge about mechanisms used by tumors for their approach to 
communicate with immune cells, which has attributed development of therapeutic drugs that 
target molecular mechanisms used by cancer to hinder their immunoregulatory role. CAFs are 
one of the major cell types found in tumor stroma that promote immunomodulation through 
secretion of various cytokines and chemokines. This has resulted in therapeutic strategies 
targeting CAFs and the pathways this cell type uses to utilize its regulatory functions. But to 
further improve and generate more effective therapeutic approaches related to CAFs, additional 
understanding about CAFs themselves and their secretory profile is needed. However, this work 
is quite challenging due to the vast heterogenic origin of CAFs. It is also believed that tumor 
stroma includes CAFs with different phenotypes which further increases the difficulties trying 
to understand and characterize this cell type. 
Future studies to understand the correlation between CAFs and DCs could include: (i) target 
factors secreted by CAFs that induces a tolerogenic TME, (ii) determine possible DCs signaling 
pathways changed by CAFs involved in the tolerogenic phenotype (iii) using in vivo models 
(iv) gain more insight about other immune cells such as macrophages, NK cells and T cells, 
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